JOINT Corp 10-Q for FY2026 Q3
JOINT Corp (JYNT)
10-Q
2026-11-06
For: 2026-09-30
View Original
Added on
November 06, 2026
About this 10-Q
JOINT Corp filed this 10-Q on November 6, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
JOINT Corp reported revenue growth of $3.8 million as franchise expansion offset weaker clinics, while third-quarter comp sales fell 1.9% and system-wide sales declined 3.1% to $123.3 million. The network operated 930 clinics as of September 30, 2026. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $13.55M
- up 1.3% from $13.38M a year earlier
- Net loss
- $117.36K
- compared with net income of $855.01K a year earlier
- Diluted EPS
- -$0.01
- compared with $0.06 a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the quarterly period ended September 30, 2026
OR
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||
For the transition period from __________________ to _________________
Commission file number: 001-36724
The Joint Corp .
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) | ||||
(Address of principal executive offices) | (Zip Code) | ||||
(480 ) 245-5960
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
The | ||||||||
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||||||||||
| ☑ | Smaller reporting company | |||||||||||||
| Emerging growth company | ||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
As of November 2, 2026, the registrant had 13,689,211 shares of Common Stock ($0.001 par value) outstanding.
THE JOINT CORP.
FORM 10-Q
TABLE OF CONTENTS
| PAGE NO. | ||||||||
Condensed Consolidated Balance Sheets as of September 30, 2026 (unaudited) and December 31, 2025 | ||||||||
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025 (unaudited) | ||||||||
Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Nine Months Ended September 30, 2026 and 2025 (unaudited) | ||||||||
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025 (unaudited) | ||||||||
Forward-Looking Statements
This Quarterly Report on Form 10-Q, especially in the Management’s Discussion and Analysis, contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, included or incorporated in this Quarterly Report on Form 10-Q could be deemed forward-looking statements, particularly statements about our plans, strategies and prospects under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” “intend,” “seek,” “strive,” or the negative of these terms, “mission,” “goal,” “objective,” or “strategy,” or other comparable terminology. All forward-looking statements in this Quarterly Report on Form 10-Q are made based on our current expectations, forecasts, estimates and assumptions and involve risks, uncertainties and other factors that could cause results or events to differ materially from those expressed in the forward-looking statements. In evaluating these statements, you should specifically consider various factors, uncertainties and risks that could affect our future results or operations as described from time to time in our Securities and Exchange Commission (“SEC”) reports, including those risks outlined under “Risk Factors” which are contained in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 13, 2026, and in Part II, Item 1A of this or any subsequent quarterly reports on Form 10-Q. These factors, uncertainties and risks may cause our actual results to differ materially from any forward-looking statement set forth in this Quarterly Report on Form 10-Q. You should carefully consider the trends, risks and uncertainties described below and other information contained in the reports we file with or furnish to the SEC before making any investment decision with respect to our securities. We undertake no obligation to update or revise publicly any forward-looking statements, other than in accordance with legal and regulatory obligations. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.
The specific forward-looking statements in this Quarterly Report on Form 10-Q include the following:
•the expected adoption and impact of recent accounting pronouncements;
•the outcome and impact on our company of any litigation in which we are involved;
•our plan to continue our franchised-focused expansion of chiropractic clinics in key markets throughout North America, and potentially abroad, as we seek to be the leading provider of chiropractic care in the markets we serve and to become the most recognized brand in our industry;
•our belief that our monthly performance reports from our system and our clinics include key performance indicators per clinic, including gross sales, comparable same-store sales growth, or “Comp Sales,” number of new patients, conversion percentage and membership attrition;
•our plan to refranchise or sell the full portfolio of our company-owned or managed clinics, which refined strategy will leverage our greatest strength - our capacity to build a franchise - to drive long-term growth for both our franchisees and The Joint as a public company;
•our plan to continue to leverage the power of the regional developer program to accelerate the number of clinics sold, and eventually opened, across the country;
•our belief that we continue to have a sound business concept and will benefit from the fundamental changes taking place in the manner in which Americans access chiropractic care and their growing interest in seeking effective, affordable natural solutions for general wellness;
•our belief that these trends join with the preference we have seen among chiropractic doctors to reject the insurance-based model resulting in a combination that benefits the consumer and the service provider alike, and our belief that these forces create an important opportunity to accelerate the growth of our network;
•our belief that recent events that may impact our business include unfavorable global economic or political conditions, continued labor shortages, and inflation and other cost increases;
•our anticipation that 2026 will continue to be a volatile macroeconomic environment;
•our goal to generate significant proceeds that will provide us with value creating capital allocation opportunities, which opportunities could include, but are not limited to, reinvestment in the brand and related marketing, continued investment in our IT platforms, the repurchase of regional development territories, certain merger or acquisition opportunities and/or additional stock repurchase programs;
•our belief that our operating results may fluctuate significantly as a result of a variety of factors, including the timing of new clinic sales, openings, closures, markets in which they are contained and related expenses, general economic conditions, cost inflation, labor shortages, elevated gas prices, consumer confidence in the economy, consumer preferences, competitive factors, and disease epidemics and other health-related concerns;
•our belief that our existing cash and cash equivalents, our anticipated cash flows from operations and amounts available under our line of credit will be sufficient to fund our anticipated operating and investment needs for at least the next 12 months;
•our belief that we have adequate capital resources and sufficient access to external financing sources to satisfy our current and reasonably anticipated requirements for funds to conduct our operations and meet other needs in the ordinary course of our business; and
•our expectation that for the remainder of 2026, we expect to use or redeploy our cash resources to support our business within the context of prevailing market conditions, which, given the ongoing uncertainties described above, could rapidly and materially deteriorate or otherwise change.
Factors that could contribute to these differences include, but are not limited to, our inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage and an increase in operating expenses due to measures we may need to take to address such shortage; inflation, leading to increased labor costs and interest rates, as well as changes to import tariffs and increased gas prices, may lead to reduced discretionary spending, all of which may negatively impact our business; our failure to profitably operate company-owned or managed clinics; our failure to refranchise as planned; short-selling strategies and negative opinions posted on the internet, which could drive down the market price of our common stock and result in class action lawsuits; our failure to remediate future material weaknesses in our internal control over financial reporting, which could negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence; and other factors described in our filings with the SEC, including in the section entitled “Risk Factors” in this Quarterly Report on Form 10-Q and subsequent filings with the SEC.
Additionally, there may be other risks that are otherwise described from time to time in the reports that we file with the SEC. Any forward-looking statements in this Quarterly Report on Form 10-Q should be considered in light of various important factors, including the risks and uncertainties listed above, as well as others.
PART I: FINANCIAL INFORMATION
ITEM 1. UNAUDITED FINANCIAL STATEMENTS
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, 2026 | December 31, 2025 | ||||||||||
| ASSETS | (unaudited) | ||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | $ | |||||||||
| Restricted cash | |||||||||||
| Accounts receivable, net | |||||||||||
| Notes receivable | |||||||||||
| Deferred franchise and regional development costs, current portion | |||||||||||
| Prepaid expenses and other current assets | |||||||||||
Discontinued operations current assets ($ | |||||||||||
| Total current assets | |||||||||||
| Property and equipment, net | |||||||||||
| Operating lease right-of-use asset | |||||||||||
| Notes receivable, net of current portion | |||||||||||
| Deferred franchise and regional development costs, net of current portion | |||||||||||
| Deposits and other assets | |||||||||||
| Total assets | $ | $ | |||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | $ | |||||||||
| Accrued expenses | |||||||||||
| Co-op funds liability | |||||||||||
| Payroll liabilities | |||||||||||
| Operating lease liability, current portion | |||||||||||
| Deferred franchise fee revenue, current portion | |||||||||||
| Upfront regional developer fees, current portion | |||||||||||
| Other current liabilities | |||||||||||
Discontinued operations current liabilities ($ | |||||||||||
| Total current liabilities | |||||||||||
| Operating lease liability, net of current portion | |||||||||||
| Deferred franchise fee revenue, net of current portion | |||||||||||
| Upfront regional developer fees, net of current portion | |||||||||||
| Total liabilities | |||||||||||
| Commitments and contingencies (Note 10) | |||||||||||
| Stockholders' equity: | |||||||||||
Series A preferred stock, $ | |||||||||||
Common stock, $ | |||||||||||
| Additional paid-in capital | |||||||||||
1
Treasury stock | ( | ( | |||||||||
| Accumulated deficit | ( | ( | |||||||||
| Total The Joint Corp. stockholders' equity | |||||||||||
| Non-controlling interest | |||||||||||
| Total equity | |||||||||||
| Total liabilities and stockholders' equity | $ | $ | |||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Revenues: | ||||||||||||||||||||||||||
| Royalty fees | $ | $ | $ | $ | ||||||||||||||||||||||
| Franchise fees | ||||||||||||||||||||||||||
| Advertising fund revenue | ||||||||||||||||||||||||||
| Software fees | ||||||||||||||||||||||||||
| Other revenues | ||||||||||||||||||||||||||
| Total revenues | ||||||||||||||||||||||||||
| Cost of revenues: | ||||||||||||||||||||||||||
| Franchise and regional developer cost of revenues | ||||||||||||||||||||||||||
| IT cost of revenues | ||||||||||||||||||||||||||
| Total cost of revenues | ||||||||||||||||||||||||||
| Selling and marketing expenses | ||||||||||||||||||||||||||
| Depreciation and amortization | ||||||||||||||||||||||||||
| General and administrative expenses | ||||||||||||||||||||||||||
Total selling, general and administrative expenses | ||||||||||||||||||||||||||
| Net loss on disposition or impairment | ||||||||||||||||||||||||||
| Income (loss) from continuing operations | ( | |||||||||||||||||||||||||
| Other income, net | ||||||||||||||||||||||||||
| Income (loss) before income tax expense | ( | |||||||||||||||||||||||||
| Income tax expense | ||||||||||||||||||||||||||
| Net income (loss) from continuing operations | ( | |||||||||||||||||||||||||
| Discontinued operations: | ||||||||||||||||||||||||||
| (Loss) income from discontinued operations before income tax expense | ( | ( | ||||||||||||||||||||||||
| Income tax (benefit) expense from discontinued operations | ( | |||||||||||||||||||||||||
| Net (loss) income from discontinued operations | ( | ( | ||||||||||||||||||||||||
| Net (loss) income | $ | ( | $ | $ | $ | |||||||||||||||||||||
| Net income (loss) from continuing operations per common share: | ||||||||||||||||||||||||||
| Basic | $ | $ | $ | $ | ( | |||||||||||||||||||||
| Diluted | $ | $ | $ | $ | ( | |||||||||||||||||||||
| Net (loss) income from discontinued operations per common share: | ||||||||||||||||||||||||||
| Basic | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||
| Diluted | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||
| Net (loss) income per common share: | ||||||||||||||||||||||||||
| Basic | $ | ( | $ | $ | $ | |||||||||||||||||||||
| Diluted | $ | ( | $ | $ | $ | |||||||||||||||||||||
| Basic weighted average shares | ||||||||||||||||||||||||||
| Diluted weighted average shares | ||||||||||||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(unaudited)
| Common Stock | Additional Paid-In Capital | Treasury Stock | Accumulated Deficit | Total The Joint Corp. Stockholders' Equity | Non-controlling Interest | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, December 31, 2025 | $ | $ | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of restricted stock, net of forfeitures | ( | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Exercise of stock options | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of treasury stock under employee stock plans | — | — | — | ( | — | ( | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock repurchased under authorized stock repurchase programs | — | — | — | ( | — | ( | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, March 31, 2026 (unaudited) | $ | $ | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of restricted stock, net of forfeitures | ( | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of treasury stock under employee stock plans | — | — | — | ( | — | ( | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock repurchased under authorized stock repurchase programs | — | — | — | ( | — | ( | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, June 30, 2026 (unaudited) | $ | $ | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of restricted stock, net of forfeitures | ( | ( | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of treasury stock under employee stock plans | — | — | — | ( | — | ( | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock repurchased under authorized stock repurchase programs | — | — | — | ( | — | ( | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | ( | ( | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||
| Balances, September 30, 2026 (unaudited) | $ | $ | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
4
| Common Stock | Additional Paid-In Capital | Treasury Stock | Accumulated Deficit | Total The Joint Corp. Stockholders' Equity | Non-controlling Interest | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, December 31, 2024 | $ | $ | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of restricted stock, net of forfeitures | ( | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Exercise of stock options | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchases of treasury stock under employee stock plans | — | — | — | ( | — | ( | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, March 31, 2025 (unaudited) | $ | $ | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of restricted stock, net of forfeitures | ( | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, June 30, 2025 (unaudited) | $ | $ | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of restricted stock, net of forfeitures | ( | ( | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Exercise of stock options | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock repurchased under authorized stock repurchase programs | — | — | — | ( | — | ( | — | ( | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Balances, September 30, 2025 (unaudited) | $ | $ | $ | ( | $ | ( | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
| Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| Cash flows from operating activities: | ||||||||||||||
| Net income | $ | $ | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||
| Depreciation and amortization | ||||||||||||||
| Net loss on disposition or impairment | ||||||||||||||
| Net franchise fees recognized upon termination of franchise agreements | ( | ( | ||||||||||||
| Provision for credit losses | ||||||||||||||
| Stock-based compensation expense | ||||||||||||||
| Changes in operating assets and liabilities: | ||||||||||||||
| Accounts receivable | ||||||||||||||
| Prepaid expenses and other current assets | ( | ( | ||||||||||||
| Deferred franchise costs | ||||||||||||||
| Deposits and other assets | ( | |||||||||||||
| Accounts payable | ( | ( | ||||||||||||
| Accrued expenses | ( | ( | ||||||||||||
| Payroll liabilities | ( | ( | ||||||||||||
| Operating leases | ( | ( | ||||||||||||
| Deferred revenue | ( | ( | ||||||||||||
| Upfront regional developer fees | ( | ( | ||||||||||||
| Other liabilities | ||||||||||||||
| Net cash provided by (used in) operating activities | ( | |||||||||||||
| Cash flows from investing activities: | ||||||||||||||
| Proceeds from sale of clinics | ||||||||||||||
| Purchase of property and equipment | ( | ( | ||||||||||||
| Net cash provided by investing activities | ||||||||||||||
| Cash flows from financing activities: | ||||||||||||||
| Payments of finance lease obligation | ( | |||||||||||||
| Purchases of treasury stock under employee stock plans | ( | ( | ||||||||||||
| Purchases of common stock under stock repurchase programs | ( | ( | ||||||||||||
| Proceeds from exercise of stock options | ||||||||||||||
| Net cash used in financing activities | ( | ( | ||||||||||||
| (Decrease) increase in cash, cash equivalents and restricted cash | ( | |||||||||||||
| Cash, cash equivalents and restricted cash, beginning of period | ||||||||||||||
| Cash, cash equivalents and restricted cash, end of period | $ | $ | ||||||||||||
| Reconciliation of cash, cash equivalents and restricted cash: | September 30, 2026 | September 30, 2025 | ||||||||||||
| Cash and cash equivalents | $ | $ | ||||||||||||
| Restricted cash | ||||||||||||||
| Cash, cash equivalents and restricted cash, end of period | $ | $ | ||||||||||||
6
Supplemental cash flow disclosures:
The following table represents supplemental cash flow disclosures and non-cash investing and financing activities:
| Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| Net cash paid for: | ||||||||||||||
| Interest | $ | $ | ||||||||||||
| Income taxes, net of refunds | ||||||||||||||
| Non-cash investing and financing activity: | ||||||||||||||
| Unpaid purchases of property and equipment | ||||||||||||||
| Notes receivable for the sale of clinics | ||||||||||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
7
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Note 1: Nature of Operations and Summary of Significant Accounting Policies
Basis of Presentation
These unaudited financial statements represent the condensed consolidated financial statements of The Joint Corp. (“The Joint”), which includes its variable interest entities (“VIEs”), and its wholly owned subsidiary, TJC Platforms, LLC (collectively, the “Company”). The accompanying unaudited condensed consolidated financial statements reflect all adjustments which are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Such unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with The Joint Corp. and Subsidiary and Affiliates consolidated financial statements and the notes thereto as set forth in our Annual Report on Form 10-K as of and for the year ended December 31, 2025, filed with the SEC on March 13, 2026, which included all disclosures required by GAAP. The results of operations for the three and nine months ended September 30, 2026 and 2025 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the three and nine month periods ended September 30, 2026 and 2025 is unaudited.
The results of operations of the corporate clinic segment are reported in (Loss) income from discontinued operations before income tax expense in the condensed consolidated statements of operations for all periods presented and the related assets and liabilities associated with discontinued operations are classified as discontinued operations current assets and liabilities in the condensed consolidated balance sheets at September 30, 2026 and December 31, 2025. The condensed consolidated statements of cash flows include cash flows related to the discontinued operations and accordingly, cash flow amounts for discontinued operations are disclosed in Note 3, Divestitures. All results and information in the condensed consolidated financial statements are presented as continuing operations and exclude the corporate clinic segment unless otherwise noted specifically as discontinued operations. For additional information, refer to Note 3, Divestitures.
Principles of Consolidation
Comprehensive (Loss) Income
Net (loss) income was the same as comprehensive (loss) income for the three and nine months ended September 30, 2026 and 2025.
Nature of Operations
The Joint Corp., a Delaware corporation, was formed on March 10, 2010, for the principal purpose of franchising and developing chiropractic clinics, selling regional developer rights, supporting the operations of franchised chiropractic clinics, and operating and managing corporate chiropractic clinics at locations throughout the United States. The franchising of chiropractic clinics is regulated by the Federal Trade Commission and various state authorities.
8
The following table summarizes the number of clinics in operation under franchise agreements and as company-owned or managed clinics for the three and nine months ended September 30, 2026 and 2025:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| Franchised clinics: | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Clinics open at the beginning of the period | |||||||||||||||||||||||
| Opened during the period | |||||||||||||||||||||||
| Acquired during the period | |||||||||||||||||||||||
| Closed during the period | ( | ( | ( | ( | |||||||||||||||||||
| Clinics in operation at the end of the period | |||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| Company-owned or managed clinics: | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Clinics open at the beginning of the period | |||||||||||||||||||||||
| Sold during the period | ( | ( | ( | ( | |||||||||||||||||||
| Closed during the period | ( | ( | ( | ( | |||||||||||||||||||
| Clinics in operation at the end of the period | |||||||||||||||||||||||
| Total clinics in operation at the end of the period | |||||||||||||||||||||||
| Clinic licenses sold but not yet developed at the end of the period | |||||||||||||||||||||||
| Future clinic licenses subject to executed letters of intent at the end of the period | |||||||||||||||||||||||
Variable Interest Entities
Certain states prohibit the “corporate practice of chiropractic,” which restricts business corporations from practicing chiropractic care by exercising control over clinical decisions by chiropractic doctors. In states that prohibit the corporate practice of chiropractic, we typically enter into long-term management agreements with professional corporations (“PCs”) that are owned by licensed chiropractic doctors, which, in turn, employ or contract with doctors who provide professional chiropractic care in our clinics. Under these management agreements with PCs, we provide, on an exclusive basis, all non-clinical services of the chiropractic practice. We have entered into such management agreements with four PCs. In connection with the sale of five company-owned or managed clinics in the Kansas City region, we terminated our management agreement with one PC as of June 30, 2025. If an entity is deemed to be the primary beneficiary of a VIE, the entity is required to consolidate the VIE in its financial statements. An entity is deemed to be the primary beneficiary of a VIE if it has both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance, and (b) the obligation to absorb the majority of losses of the VIE or the right to receive the majority of benefits from the VIE. In accordance with relevant accounting guidance, these PCs were determined to be VIEs, as fees paid by the PCs to us for management services are considered variable interests because the fees do not meet all the following criteria: (1) the fees are compensation for services provided and are commensurate with the level of effort required to provide those services; (2) the decision maker or service provider does not hold other interests in the VIE that individually, or in the aggregate, would absorb more than an insignificant amount of the VIE’s expected losses or receive more than an insignificant amount of the VIE’s expected residual returns; and (3) the service arrangement includes only terms, conditions, or amounts that are customarily present in arrangements for similar services negotiated at arm’s length. Additionally, we have determined that we have the ability to direct the activities that most significantly impact the performance of these PCs and we have an obligation to absorb losses or receive benefits which could potentially be significant to the PCs. Accordingly, the PCs are VIEs for which we are the primary beneficiary and are consolidated by us.
The revenues of VIEs represent the revenues of company-managed clinics in states that prohibit the corporate practice of chiropractic. Our involvement with VIEs affects our financial performance and cash flows primarily through amounts recorded as revenues from company-owned or managed clinics and general and administrative expenses, which are principally comprised of payroll and related expenses, merchant card fees and insurance expense, all of which are reported in (Loss) income from
9
discontinued operations before income tax expense in our condensed consolidated statements of operations. The management fees/income provided by the management agreements are considered intercompany transactions and therefore eliminated upon consolidation of VIEs.
VIE net income (including the management fee) for the three and nine months ended September 30, 2026 and 2025, respectively, is included in (Loss) income from discontinued operations before income tax expense and Income tax (benefit) expense from discontinued operations in the condensed consolidated statements of operations as follows:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Income from discontinued operations before income tax | $ | $ | $ | $ | |||||||||||||||||||
| Income tax (benefit) expense from discontinued operations | ( | ||||||||||||||||||||||
| Net income | $ | $ | $ | $ | |||||||||||||||||||
The carrying amount of the VIEs’ assets and liabilities is included in discontinued operations as of September 30, 2026 and December 31, 2025 in the condensed consolidated balance sheets as follows:
| September 30, 2026 | December 31, 2025 | ||||||||||
| Discontinued operations current assets | $ | $ | |||||||||
| Discontinued operations current liabilities | |||||||||||
Cash and Cash Equivalents
Restricted Cash
Restricted cash relates to cash that franchisees and company-owned or managed clinics contribute to our National Marketing Fund and cash that franchisees provide to various voluntary regional Co-Op Marketing Funds. Cash contributed by franchisees to the National Marketing Fund is to be used in accordance with our Franchise Disclosure Document with a focus on regional and national marketing and advertising. While such cash balances are not legally segregated and restricted as to withdrawal or usage, our accounting policy is to classify these funds as restricted cash.
Accounts Receivable and Allowance for Credit Losses
10
The following table provides a reconciliation of the activity related to our allowance for credit losses:
| Allowance for Credit Losses | |||||
| Balance at December 31, 2024 | $ | ||||
| Bad debt expense recognized during the year | |||||
| Write-off of uncollectible amounts, net of recoveries | ( | ||||
| Balance at December 31, 2025 | $ | ||||
| Bad debt expense recognized during the period | |||||
| Write-off of uncollectible amounts, net of recoveries | ( | ||||
| Balance at September 30, 2026 | $ | ||||
Notes Receivable
Notes receivable consists primarily of amounts due from buyers of certain previously company-owned or managed clinics in the Southeast and Northern California regions. Certain buyers entered into promissory notes for the purchase price of their clinics or for the franchise fees associated with operating the purchased clinics. Notes are carried at amortized cost, net of an allowance for credit losses, when appropriate. Interest income is recognized using the effective interest method. Notes are placed on nonaccrual status when payments are 90 days or more past due or when management determines collection is not reasonably assured. Interest received on nonaccrual notes is applied to the principal. Notes are written off when deemed uncollectible.
Property and Equipment
Leases
We lease property and equipment under operating leases. We lease our corporate office space and the space for each of the company-owned or managed clinics in the portfolio. We recognize a right-of-use (“ROU”) asset and lease liability for all leases. The lease for our corporate office space is recognized as a ROU asset and lease liability in our condensed consolidated balance sheets as continuing operations while all other leases for each of the company-owned or managed clinics are reported in discontinued operations. Certain leases include one or more renewal options, generally for the same period as the initial term of the lease. The exercise of lease renewal options is generally at our sole discretion and, as such, we typically determine that exercise of these renewal options is not reasonably certain. As a result, we do not include the renewal option period in the expected lease term and the associated lease payments are not included in the measurement of the ROU asset and lease liability. When available, we use the rate implicit in the lease to discount lease payments; however, the rate implicit in the lease is not readily determinable for substantially all of our leases. In such cases, we estimate our incremental borrowing rate as the interest rate we would pay to borrow an amount equal to the lease payments over a similar term, with similar collateral as in the lease and in a similar economic environment. We estimate these rates using available evidence such as rates imposed by third-party lenders to us in recent financings or observable risk-free interest rate and credit spreads for commercial debt of a similar duration, with credit spreads correlating to our estimated creditworthiness.
For operating leases that include rent holidays and rent escalation clauses, we recognize lease expense on a straight-line basis over the lease term from the date we take possession of the leased property. Pre-opening costs are recorded as incurred in general and administrative expenses. Variable lease payments, such as percentage rentals based on location sales, periodic adjustments for inflation, reimbursement of real estate taxes, any variable common area maintenance and any other variable costs associated with the leased corporate office space are expensed as incurred in general and administrative expenses in the condensed consolidated
11
statements of operations. Any variable costs associated with the leased property for company-owned or managed clinics are expensed as incurred and are included in (Loss) income from discontinued operations before income tax expense in the condensed consolidated statements of operations.
During the three and nine months ended September 30, 2026 and 2025, certain leases related to discontinued operations were terminated early with the landlord as a result of corporate clinic closures. The net losses to terminate the leases were recorded in (Loss) income from discontinued operations before income tax in the condensed consolidated statements of operations of $0.4 million and $0.1 million for the three and nine months ended September 30, 2026, respectively. The net losses to terminate the leases were recorded in Income from discontinued operations before income tax in the condensed consolidated statements of operations of $0.3 million and $0.7 million for the three and nine months ended September 30, 2025, respectively.
Long-Lived Assets
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Net loss on impairment on assets held for sale related to discontinued operations | $ | $ | $ | $ | ||||||||||||||||||||||
A valuation allowance of $2.5 million and $6.3 million as of September 30, 2026 and December 31, 2025, respectively, is included in Discontinued operations current assets on the condensed consolidated balance sheets.
The following table shows a reconciliation of our impairment and disposal losses recorded in (Loss) income from discontinued operations before income tax expense for the three and nine months ended September 30, 2026 and 2025:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Impairment on assets held for sale | ||||||||||||||||||||||||||
| Assets held for sale | $ | $ | $ | $ | ||||||||||||||||||||||
| Loss on disposal of assets other than by sale | ||||||||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||||||||||||
| Loss on the sale of assets | ||||||||||||||||||||||||||
| Total net loss on disposition or impairment related to discontinued operations | $ | $ | $ | $ | ||||||||||||||||||||||
Revenue Recognition
We generate revenue primarily through company-owned or managed clinics and through royalties, franchise fees, advertising fund contributions, IT-related income and computer software fees from our franchisees.
12
Revenues from Company-Owned or Managed Clinics. We earn revenues from clinics we own and operate or manage throughout the United States. Revenues from company-owned or managed clinics are recognized when services are performed and are related to discontinued operations. We offer a variety of membership and wellness packages, which feature discounted pricing as compared with our single-visit pricing. Amounts collected in advance for membership and wellness packages are recorded as deferred revenue and recognized when the service is performed. Any unused visits associated with monthly memberships are recognized on a month-to-month basis. We recognize a contract liability (or a deferred revenue liability) related to the prepaid treatment plans for which we have an ongoing performance obligation. We derecognize this contract liability and recognize revenue, as the patient consumes his or her visits related to the package and we transfer our services. If we determine that we are not subject to unclaimed property laws for the portion of wellness package that we do not expect to be redeemed (referred to as “breakage”), then we recognize breakage revenue in proportion to the pattern of exercised rights by the patient.
Royalties and Advertising Fund Revenue. We collect royalties as stipulated in the franchise agreement, equal to 7 % of gross sales and a marketing and advertising fee currently equal to 2 % of gross sales. Royalties, including franchisee contributions to advertising funds, are calculated as a percentage of clinic sales over the term of the franchise agreement. The revenue accounting standard provides an exception for the recognition of sales-based royalties promised in exchange for a license (which generally requires a reporting entity to estimate the amount of variable consideration to which it will be entitled in the transaction price). As the franchise agreement royalties, inclusive of advertising fund contributions, represent sales-based royalties that are related entirely to our performance obligation under the franchise agreement, such sales-based royalties are recognized as franchisee clinic level sales occur. Royalties are collected semi-monthly, two working days after each sales period has ended.
Franchise Fees. We require the entire non-refundable initial franchise fee to be paid upon execution of a franchise agreement, which typically has an initial term of 10 years. Initial franchise fees are recognized ratably on a straight-line basis over the term of the franchise agreement. Our services under the franchise agreement include training of franchisees and staff, site selection, construction/vendor management and ongoing operations support. With the exception of the franchise fees for certain recently sold company-owned or managed clinics in the Southeast region, we provide no financing to franchisees and offer no guaranties on their behalf. The services provided by us are highly interrelated with the franchise license and as such are considered to represent a single performance obligation. Renewal franchise fees, as well as transfer fees, are also recognized as revenue on a straight-line basis over the term of the respective franchise agreement.
Software Fees. We collect a monthly fee from our franchisees for use of our proprietary chiropractic software, computer support and internet services support. These fees are recognized ratably on a straight-line basis over the term of the respective franchise agreement.
Capitalized Sales Commissions. Sales commissions earned by the regional developers and our sales force are considered incremental and recoverable costs of obtaining a franchise agreement with a franchisee. These costs are deferred and then amortized as the respective franchise fees are recognized ratably on a straight-line basis over the term of the franchise agreement.
Regional Developer Fees
We have a regional developer program where regional developers are granted an exclusive geographical territory and commit to a minimum development obligation within that defined territory. Upon receiving exclusive rights to develop a territory, a regional developer will pay an upfront fee to us. Upfront regional developer fees represent consideration received from a vendor to act as our agent within an exclusive territory. The upfront regional developer fee is accounted for as a reduction of cost of revenues, in franchise and regional developer cost of revenues, to offset the respective future commissions paid to the regional developer. The fees are ratably recognized over the term of the related regional developer agreement.
13
Regional Developer Rights Contract Termination Costs
Advertising Costs
Income Taxes
Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date pre-tax income, plus any significant unusual or infrequently occurring items that are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected pre-tax income for the year and permanent differences. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or the tax environment changes.
(Loss) Earnings per Common Share
Basic (loss) earnings per common share is computed by dividing the net (loss) income by the weighted-average number of common shares outstanding during the period. Diluted (loss) earnings per common share is computed by giving effect to all potentially dilutive common shares including restricted stock and stock options.
14
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Net income (loss) from continuing operations | $ | $ | $ | $ | ( | ||||||||||||||||||
| Net (loss) income from discontinued operations | ( | ( | |||||||||||||||||||||
| Net (loss) income | $ | ( | $ | $ | $ | ||||||||||||||||||
| Weighted average common shares outstanding - basic | |||||||||||||||||||||||
| Effect of dilutive securities: | |||||||||||||||||||||||
| Unvested restricted stock and stock options | |||||||||||||||||||||||
| Weighted average common shares outstanding - diluted | |||||||||||||||||||||||
| (Loss) income per share: | |||||||||||||||||||||||
| Basic (loss) income per share: | |||||||||||||||||||||||
| Continuing operations | $ | $ | $ | $ | ( | ||||||||||||||||||
| Discontinued operations | ( | ( | |||||||||||||||||||||
| Net (loss) income per basic share | $ | ( | $ | $ | $ | ||||||||||||||||||
| Diluted (loss) income per share | |||||||||||||||||||||||
| Continuing operations | $ | $ | $ | $ | ( | ||||||||||||||||||
| Discontinued operations | ( | ( | |||||||||||||||||||||
| Net (loss) income per diluted share | $ | ( | $ | $ | $ | ||||||||||||||||||
The following common stock equivalents were excluded from the computation of diluted (loss) earnings per share for the periods presented because including them would have been antidilutive:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Stock options | |||||||||||||||||||||||
Stock-Based Compensation
We account for share-based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. We determine the estimated grant-date fair value of restricted shares using the closing price on the date of the grant and the grant-date fair value of stock options using the Black-Scholes-Merton model. In order to calculate the fair value of stock options, certain assumptions are made regarding the components of the model, including risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to the valuation. We recognize compensation costs ratably over the period of service using the straight-line method. Forfeitures are estimated based on historical and forecasted turnover, which is approximately 5 %.
Loss Contingencies
ASC Topic 450 governs the disclosure of loss contingencies and accrual of loss contingencies in respect of litigation and other claims. We record an accrual for a potential loss when it is probable that a loss will occur and the amount of the loss can be reasonably estimated. When the reasonable estimate of the potential loss is within a range of amounts, the minimum of the range of potential loss is accrued, unless a higher amount within the range is a better estimate than any other amount within the range. Moreover, if an accrual is not required, we provide additional disclosure related to litigation and other claims when it is
15
reasonably possible (i.e., more than remote) that the outcomes of such litigation and other claims include potential material adverse impacts on us. Legal costs to be incurred in connection with a loss contingency are expensed as such costs are incurred.
Use of Estimates
Recent Accounting Pronouncements Adopted and Not Yet Adopted
In December 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires public entities to provide greater disaggregation within their annual rate reconciliation, including new requirements to present reconciling items on a gross basis in specified categories, disclose both percentages and dollar amounts and disaggregate individual reconciling items by jurisdiction and nature when the effect of the items meet a quantitative threshold. The guidance also requires disaggregating the annual disclosure of income taxes paid, net of refunds received, by federal (national), state and foreign taxes, with separate presentation of individual jurisdictions that meet a quantitative threshold. The guidance is effective for annual periods beginning after December 15, 2024, on a prospective basis, with a retrospective option, and early adoption is permitted. We adopted ASU 2023-09 for the year ended December 31, 2025. There was no material effect on our condensed consolidated financial statements and disclosures.
Note 2: Revenue Disclosures
Franchising Fees, Royalty Fees, Advertising Fund Revenue, and Software Fees
As of September 30, 2026, we had 915 franchised clinics in operation, 47 clinic licenses sold but not yet developed and 57 executed letters of intent for future clinic licenses. The franchise arrangement is documented in the form of a franchise agreement. The franchise arrangement requires us to perform various activities to support the brand that do not directly transfer goods and services to the franchisee, but instead represent a single performance obligation, which is the transfer of the franchise license. The intellectual property subject to the franchise license is symbolic intellectual property as it does not have significant standalone functionality and substantially all of the utility is derived from its association with our past or ongoing activities. The nature of our promise in granting the franchise license is to provide the franchisee with access to the brand’s symbolic intellectual property over the term of the license. The services provided by us are highly interrelated with the franchise license and as such are considered to represent a single performance obligation.
The transaction price in a standard franchise arrangement primarily consists of (a) initial franchise fees, (b) continuing franchise fees (royalties), (c) advertising fees, and (d) software fees. The revenue accounting standard provides an exception for the recognition of sales-based royalties promised in exchange for a license (which otherwise requires a reporting entity to estimate the amount of variable consideration to which it will be entitled in the transaction price).
16
We recognize the primary components of the transaction price as follows:
•Initial and renewal franchise fees, as well as transfer fees, are recognized as revenue ratably on a straight-line basis over the term of the respective franchise agreement, commencing with the execution of the franchise, renewal or transfer agreement. As these fees are typically received in cash at or near the beginning of the contract term, the cash received is initially recorded as a contract liability until recognized as revenue over time.
•We are entitled to royalties and advertising fees based on a percentage of the franchisee’s gross sales as defined in the franchise agreement. Royalty and advertising revenue are recognized when the franchisee’s sales occur. Depending on timing within a fiscal period, the recognition of revenue results in either what is considered a contract asset (unbilled receivable) or, once billed, accounts receivable, on the condensed consolidated balance sheets.
•We are entitled to a software fee, which is charged monthly. We recognize revenue related to software fees ratably on a straight-line basis over the term of the franchise agreement.
In determining the amount and timing of revenue from contracts with customers, we exercise significant judgment with respect to collectability of the amount; however, the timing of recognition does not require significant judgment as it is based on either the franchise term or the reported sales of the franchisee, neither of which requires estimation. We believe that our franchising arrangements do not contain a significant financing component.
We recognize advertising fees received under franchise agreements as advertising fund revenue.
Capitalized Sales Commissions
Sales commissions earned by the regional developers and our sales force are considered incremental and recoverable costs of obtaining a franchise agreement with a franchisee. These costs are deferred and then amortized as the respective franchise fees are recognized ratably on a straight-line basis over the term of the franchise agreement.
Disaggregation of Revenue
We believe that the captions contained on the condensed consolidated statements of operations appropriately reflect the disaggregation of our revenue by major type for the three and nine months ended September 30, 2026 and 2025. Other revenues primarily consist of merchant income associated with preferred vendor royalties associated with franchisees’ credit card transactions.
The following table shows our revenues disaggregated according to the timing of transfer of services:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Revenue recognized at a point in time | $ | $ | $ | $ | |||||||||||||||||||
| Revenue recognized over time | |||||||||||||||||||||||
| Total revenue | $ | $ | $ | $ | |||||||||||||||||||
Rollforward of Accounts Receivable
Changes in our accounts receivable, net during the nine months ended September 30, 2026 were as follows:
| Accounts Receivable, Net | |||||
| Balance at December 31, 2025 | $ | ||||
| Cash received against accounts receivable included at the beginning of the year | ( | ||||
| Net increase during the nine months ended September 30, 2026 | |||||
| Allowance for credit losses | ( | ||||
| Balance at September 30, 2026 | $ | ||||
17
Rollforward of Contract Liabilities and Contract Assets
Changes in our contract liability for deferred franchise fees during the nine months ended September 30, 2026 were as follows:
| Deferred Revenue Short and Long-Term | |||||
| Balance at December 31, 2025 | $ | ||||
| Revenue recognized that was included in the contract liability at the beginning of the year | ( | ||||
| Net increase during the nine months ended September 30, 2026 | |||||
| Balance at September 30, 2026 | $ | ||||
Our deferred franchise and development costs represent capitalized sales commissions. Changes during the nine months ended September 30, 2026 were as follows:
| Deferred Franchise and Development Costs Short and Long-Term | |||||
| Balance at December 31, 2025 | $ | ||||
| Cost of revenue recognized that was included in the contract asset at the beginning of the year | ( | ||||
| Net increase during the nine months ended September 30, 2026 | |||||
| Balance at September 30, 2026 | $ | ||||
The following table illustrates estimated revenues expected to be recognized in the future related to performance obligations that were unsatisfied (or partially unsatisfied) as of September 30, 2026:
| Contract liabilities expected to be recognized in | Amount | |||||||
| 2026 (remainder) | $ | |||||||
| 2027 | ||||||||
| 2028 | ||||||||
| 2029 | ||||||||
| 2030 | ||||||||
| Thereafter | ||||||||
| Total | $ | |||||||
Note 3: Divestitures
Corporate Clinic Segment Divestiture
In 2023, we initiated plans to refranchise the majority of our company-owned or managed clinics with plans to retain a small portion of high-performing clinics. During the third quarter of 2024, we expanded the refranchising plan to include additional clinic markets of company-owned or managed clinics, marketing the clinics in clusters grouped by proximity to larger private equity firms. Because we have formalized a plan to sell our entire corporate clinic reportable segment, we have concluded that the overall refranchising plan represents a strategic shift that will have a major effect on our operations and financial results.
Since December 31, 2024, the corporate clinics classified as held for sale or already sold under the refranchising plan represent, in the aggregate, a strategic shift that will have a major effect on our operations and financial results. Accordingly, the results of the corporate clinic segment and its assets and liabilities are reported separately as discontinued operations in the condensed consolidated statements of operations and condensed consolidated balance sheets. As permitted, we elected not to adjust the condensed consolidated statements of cash flows for the nine months ended September 30, 2026 and 2025 to separately present cash flows attributable to discontinued operations. Accordingly, we disclosed the depreciation and amortization, capital expenditures and significant operating and investing non-cash items related to the corporate clinic segment below.
18
The key components of Net (loss) income from discontinued operations that were included in our condensed consolidated statements of operations are as follows:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Revenues: | ||||||||||||||||||||||||||
| Revenues from company-owned or managed clinics | $ | $ | $ | $ | ||||||||||||||||||||||
| Total revenues | ||||||||||||||||||||||||||
| Cost of revenues: | ||||||||||||||||||||||||||
| IT cost of revenues | ||||||||||||||||||||||||||
| Total cost of revenues | ||||||||||||||||||||||||||
| Selling and marketing expenses | ||||||||||||||||||||||||||
| Depreciation and amortization | ||||||||||||||||||||||||||
| General and administrative expenses | ||||||||||||||||||||||||||
| Total selling, general and administrative expenses | ||||||||||||||||||||||||||
| Net loss on disposition or impairment from discontinued operations | ||||||||||||||||||||||||||
| (Loss) income from discontinued operations | ( | ( | ||||||||||||||||||||||||
| Other expense, net | ||||||||||||||||||||||||||
| (Loss) income before income tax expense | ( | ( | ||||||||||||||||||||||||
| Income tax (benefit) expense from discontinued operations | ( | |||||||||||||||||||||||||
| Net (loss) income from discontinued operations | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||
19
The following table summarizes the major classes of assets and liabilities of discontinued operations that were included in our condensed consolidated balance sheets:
| September 30, 2026 | December 31, 2025 | |||||||||||||
| ASSETS | ||||||||||||||
| Restricted cash | $ | $ | ||||||||||||
| Accounts receivable | ||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||
| Assets held for sale, net of valuation allowance | ||||||||||||||
| Property and equipment, net | ||||||||||||||
| Deferred tax assets (attributable to VIEs) | ||||||||||||||
| Deposits and other assets | ||||||||||||||
| Total assets, discontinued operations | $ | $ | ||||||||||||
| LIABILITIES | ||||||||||||||
| Accounts payable | $ | $ | ||||||||||||
| Accrued expenses | ||||||||||||||
Payroll liabilities ( | ||||||||||||||
| Operating lease liability, current portion | ||||||||||||||
Other current liabilities ($ | ||||||||||||||
Liabilities to be disposed of ($ | ||||||||||||||
| Total liabilities, discontinued operations | $ | $ | ||||||||||||
The key components of cash flows from discontinued operations are as follows:
| Nine Months Ended September 30, | ||||||||||||||||||||||||||
| 2026 | 2025 | |||||||||||||||||||||||||
| Significant operating and investing non-cash items: | ||||||||||||||||||||||||||
| Depreciation and amortization | $ | $ | ||||||||||||||||||||||||
Net loss on disposition or impairment | ||||||||||||||||||||||||||
Capital expenditures: | ||||||||||||||||||||||||||
| Purchase of property and equipment | ||||||||||||||||||||||||||
The clustered clinics are in varying stages of sales negotiations with substantially all of the company-owned or managed clinics expected to be recognized as a completed sale within one year with an estimated fair value of $0.9 million at September 30, 2026. Effective with the designation as held for sale, we discontinued recording depreciation on property and equipment, net, amortization of intangible assets, net and amortization of ROU assets for the clinics as required by GAAP. We reported the related assets and liabilities of the clinics as held for sale as discontinued operations in our September 30, 2026 and December 31, 2025 condensed consolidated balance sheets.
Long-lived assets that meet the criteria for the held for sale designation are reported at the lower of their carrying value or fair value less estimated cost to sell. As a result of our evaluation of the recoverability of the carrying value of the assets and liabilities held for sale relative to the clinics estimated fair values, we recorded an estimated loss on disposal of $1.1 million and $0.5 million for the three months ended September 30, 2026 and 2025, respectively, and an estimated loss of $2.9 million and $1.9 million for the nine months ended September 30, 2026 and 2025, respectively. A valuation allowance of $2.5 million and $6.3 million is included in discontinued operations current assets in our condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025, respectively.
On December 5, 2025, we entered into an Asset Purchase Agreement, pursuant to which we will sell the assets of, and grant franchise rights to, 22 company-owned or managed clinics located in Virginia, North Carolina and South Carolina for an
20
aggregate purchase price of approximately $1.5 million, subject to certain adjustments. In mid-December 2025, the buyers assumed business operations under Management Service Agreements (“MSAs”) that will remain in effect until lease reassignments are completed to permit ownership transfer, for which the buyers receive a management fee in consideration for providing management services. During the quarter ended June 30, 2026, we closed on the sale of one clinic included in the transaction. During the quarter ended September 30, 2026, we closed on the sale of nine clinics included in the transaction. As of September 30, 2026, the transaction as a whole had not officially closed and therefore, the net assets and liabilities of the remaining clinics remain in our consolidated balance sheets.
On April 20, 2026, we entered into an Asset Purchase Agreement (the “Elite Chiro Group Purchase Agreement”) with Elite Chiro Group, a California corporation (“Elite Chiro Group”), as buyer, pursuant to which we will sell to Elite Chiro Group the assets of, and grant franchise rights to, 45 company-owned or managed clinics located in Southern California (the “Elite Chiro Group Transaction”) for an aggregate purchase price of $2.3 million, subject to certain adjustments (the “Purchase Price”). The Purchase Price includes prorated franchise fees pursuant to 45 separate franchise agreements to be entered into between us and Elite Chiro Group and the non-exclusive development rights for 10 clinics to be developed in the metropolitan statistical areas of a development area to be agreed upon by us and Elite Chiro Group in accordance with the schedule set forth in the Elite Chiro Group Purchase Agreement. On April 27, 2026, we closed on the sale of 13 clinics included in the Elite Chiro Group Transaction, at which time ownership of such clinics transferred to Elite Chiro Group. On April 27, 2026, Elite Chiro Group also assumed business operations for the remaining 32 clinics included in the Elite Chiro Group Transaction pursuant to an MSA. In May and June 2026, we closed on the sale of 15 additional clinics included in the Elite Chiro Group Transaction. During the quarter ended September 30, 2026, we closed on the sale of 12 clinics included in the Elite Chiro Group Transaction. As of September 30, 2026, the Elite Chiro Group Transaction as a whole had not officially closed and therefore, the net assets and liabilities of the remaining clinics remain in our consolidated balance sheets.
During the nine months ended September 30, 2026, in connection with the sale of company-owned or managed clinics classified as held for sale as of December 31, 2025 for a combined sales price of $1.4 million, we sold $17.1 million of assets held for sale net of a $4.8 million valuation allowance and $10.4 million of liabilities to be disposed of in the consolidated balance sheets as of December 31, 2025. As a result of the sales, we incurred $146 thousand in selling costs and recorded a loss of $333 thousand included in (Loss) income from discontinued operations before income tax expense in the condensed consolidated statements of operations for the nine months ended September 30, 2026.
During the nine months ended September 30, 2025, in connection with the sale of company-owned or managed clinics classified as held for sale as of December 31, 2024 for a combined sales price of $7.8 million, we sold $16.2 million of assets held for sale, net of a valuation allowance of $1.0 million and $7.3 million of liabilities to be disposed of in the consolidated balance sheets as of December 31, 2024. As a result of the sales, we incurred $0.4 million in selling costs and recorded a loss of $0.6 million included in (Loss) income from discontinued operations before income tax expense in the condensed consolidated statements of operations for the nine months ended September 30, 2025.
21
The principal components of the held for sale assets and liabilities to be disposed of as of September 30, 2026 and December 31, 2025 were as follows:
| September 30, 2026 | December 31, 2025 | ||||||||||
| ASSETS | |||||||||||
Property and equipment, net | $ | $ | |||||||||
| Operating lease right-of-use asset | |||||||||||
| Intangible assets, net | |||||||||||
| Goodwill | |||||||||||
| Valuation allowance | ( | ( | |||||||||
| Total assets held for sale, net | $ | $ | |||||||||
| LIABILITIES | |||||||||||
| Operating lease liability, current and noncurrent | $ | $ | |||||||||
| Deferred revenue from company-owned or managed clinics | |||||||||||
| Total liabilities to be disposed of | $ | $ | |||||||||
The pre-tax income of the clinics designated as held for sale as of September 30, 2026 was $0.3 million and $0.4 million for the three months ended September 30, 2026 and 2025, respectively, the results of which exclude the allocation of overhead. The pre-tax income of the clinics designated as held for sale as of September 30, 2026 was $0.7 million and $1.2 million for the nine months ended September 30, 2026 and 2025, respectively, the results of which exclude the allocation of overhead. The pre-tax income for the three and nine months ended September 30, 2026 was impacted by the management fees as noted above.
Note 4: Property and Equipment
Property and equipment consisted of the following:
| September 30, 2026 | December 31, 2025 | ||||||||||
| Office and computer equipment | $ | $ | |||||||||
| Leasehold improvements | |||||||||||
| Internally-developed software | |||||||||||
| Accumulated depreciation and amortization | ( | ( | |||||||||
| Construction in progress | |||||||||||
| Property and equipment, net | $ | $ | |||||||||
Construction in progress at September 30, 2026 and December 31, 2025 related primarily to internal use software in development.
Note 5: Fair Value Measurements
Our financial instruments include restricted cash, accounts receivable, notes receivable, accounts payable and accrued expenses. The carrying amounts of our financial instruments, excluding cash equivalents, approximate their fair value due to their short maturities. Cash equivalents consist of money market funds for which original cost approximates fair value. Cash equivalents have an approximate fair value of $12.6 million and $19.2 million as of September 30, 2026 and December 31, 2025, respectively, which were determined using Level 1 inputs.
Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability, developed based on market data obtained from sources independent of our company. Unobservable inputs are inputs that reflect our assumptions of what market participants would use in pricing the asset or liability developed
22
based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows:
Level 1: Observable inputs such as quoted prices in active markets;
Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
As of September 30, 2026 and December 31, 2025, with the exception of cash equivalents noted above, we did not have any financial instruments that were measured on a recurring basis as Level 1, 2 or 3.
Our non-financial assets, included in both continuing and discontinued operations, which primarily consist of goodwill, intangible assets, property, plant and equipment, and operating lease ROU assets, are not required to be measured at fair value on a recurring basis, and instead are reported at their carrying amount. However, on a periodic basis whenever events or changes in circumstances indicate that their carrying amount may not be fully recoverable (and at least annually for goodwill), non-financial assets are assessed for impairment. If the fair value is determined to be lower than the carrying amount, an impairment charge is recorded to write down the asset to its fair value, which is considered Level 3 within the fair value hierarchy.
Long-lived assets that meet the held for sale criteria are reported at the lower of their carrying value or fair value, less estimated costs to sell. The estimated fair values of the company-owned or managed clinics classified as Held for Sale (see Note 3, Divestitures) were recorded in discontinued operations current assets at fair values on a nonrecurring basis and are based upon Level 2 inputs, which include a potential buyer agreed-upon selling price or Level 3 inputs, which includes consideration of a market approach using a multiple of earnings assumption based on clinic-level historical financial performance as well as an income approach using discounted cash flow (“DCF”) models that use significant unobservable inputs and assumptions. Key inputs in the DCF models included projected cash flows over a 10 -year forecast period, based on clinic-level historical financial performance and management’s expectations of future operating results. A terminal value was estimated using the Gordon Growth Model for locations with positive cash flows. For locations with projected negative cash flows, no terminal value was assigned, as these clinics were assumed to cease operations upon lease termination. The future cash flows and terminal value were discounted to present value using a discount rate of 14.5 % for clinics with positive cash flows and 4.2 % for clinics with negative cash flows, which reflect the risk profile of the underlying operations and market conditions as of the measurement date.
Assets held for sale as of September 30, 2026 and December 31, 2025 include all company-owned or managed clinics. The fair value measurement of the assets held for sale as of September 30, 2026 was recorded as $0.9 million based upon Level 2 inputs. We maintain a valuation allowance of $2.5 million to adjust the carrying value of the disposal group to fair value less cost to sell as of September 30, 2026. The fair value of the assets held for sale as of December 31, 2025 was valued as $0.1 million based upon Level 2 inputs and $2.5 million based upon Level 3 inputs and carried a valuation allowance of $6.3 million to adjust the carrying value of the disposal group to fair value less cost to sell as of December 31, 2025.
Note 6: Debt
Credit Agreement
On February 28, 2020, we entered into a Credit Agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., individually and as Administrative Agent and Issuing Bank (the “Lender”). The Credit Agreement provided for senior secured credit facilities (the “Credit Facilities”) in the amount of $7.5 million, including a $2.0 million revolver (the “Revolver”) and a $5.5 million development line of credit (the “Line of Credit”). The Revolver included amounts available for letters of credit of up to $1.0 million and an uncommitted additional amount of $2.5 million. All outstanding principal and interest on the Revolver was due on February 28, 2022.
On February 28, 2022, we entered into an amendment to the Credit Facilities (as amended, the “2022 Credit Facility”) with the Lender. Under the 2022 Credit Facility, the Revolver increased to $20.0 million (from $2.0 million), the portion of the Revolver available for letters of credit increased to $5.0 million (from $1.0 million), the uncommitted additional amount increased to $30.0 million (from $2.5 million) and the developmental Line of Credit of $5.5 million was terminated. The Revolver will be used for working capital needs, general corporate purposes and for acquisitions, development and capital improvement uses. At our option, borrowings under the 2022 Credit Facility bear interest at: (i) the adjusted Secured Overnight Financing Rate (“SOFR”), plus 0.10 %, plus 1.75 %, payable on the last day of the selected interest period of one, three or six months and on the three-month anniversary of the beginning of any six-month interest period, if applicable; or (ii) an Alternative Base Rate (“ABR”), plus 1.00 %, payable monthly. The ABR is the greatest of (A) the prime rate (as published by the Wall Street Journal); (B) the Federal Reserve
23
Bank of New York rate, plus 0.5 %; and (C) the adjusted one-month term SOFR. Amounts outstanding under the Revolver on February 28, 2022 continued to bear interest at the rate selected under the Credit Facilities prior to the amendment until the last day of the interest period in effect, at which time, if not repaid, the amounts outstanding under the Revolver will bear interest at the 2022 Credit Facility rate. As a result of this refinance, $2.0 million of current maturity of long-term debt was reclassified to long-term as of December 31, 2021. The 2022 Credit Facility was originally scheduled to terminate, and all principal and interest to become due and payable on the fifth anniversary of the amendment on February 28, 2027. On January 17, 2024, we paid down the outstanding balance on our Debt under the Credit Agreement of $2.0 million.
The Credit Facilities contain customary events of default, including but not limited to nonpayment, material inaccuracy of representations and warranties, violations of covenants, certain bankruptcies and liquidations, cross-default to material indebtedness, certain material judgments, and certain fundamental changes such as a merger or sale of substantially all assets (as further defined in the Credit Facilities). The Credit Facilities require us to comply with customary affirmative, negative and financial covenants, including minimum interest coverage and maximum net leverage. A breach of any of these operating or financial covenants would result in a default under the Credit Facilities. If an event of default occurs and is continuing, the lenders could elect to declare all amounts then outstanding, together with accrued interest, to be immediately due and payable. The Credit Facilities are collateralized by substantially all of our assets, including the assets in our company-owned or managed clinics.
On September 30, 2025, we entered into a third amendment to the Credit Agreement (as amended, the “2025 Credit Facility”) with the Lender. Among other things, the 2025 Credit Facility contains the consent of the Lender to the refranchising of all company-owned or managed clinics which would have triggered certain default events included in the Credit Agreement. The 2025 Credit Facility also extended the maturity date of the Credit Facilities to August 31, 2027.
On May 1, 2026, we entered into a waiver and fourth amendment to the Credit Agreement (as amended, the “2026 Credit Facility”) with the Lender. Among other things, the 2026 Credit Facility waived the then-existing default of our Credit Facilities due to a violation of our fixed charge coverage ratio covenant and modified the fixed charge coverage ratio covenant to allow for stock repurchases, which constitute restricted payments. The 2026 Credit Facility also extended the maturity date of the Credit Facilities to August 31, 2029.
Note 7: Stockholders ' Equity
Stock Repurchase Program
On June 3, 2025, our Board of Directors approved a stock repurchase program (the “2025 SRP”) to repurchase up to $5.0 million of our common stock, par value $0.001 per share, from time to time until June 3, 2027 or such other date as we have exhausted, or the Board of Directors otherwise terminates, the repurchase authorization. On November 4, 2025, the Board of Directors authorized an additional $12.0 million under the 2025 SRP and extended the repurchase date through November 4, 2027.
The timing, volume, price, and terms of the repurchases will depend on market and business conditions, applicable legal requirements, and other factors. The repurchases may be made on the open market, in privately negotiated transactions, or in such other manner (e.g., accelerated share repurchase transactions, block trades, derivatives, or otherwise) that complies with the terms of applicable federal and state securities laws and regulations.
During the three months ended September 30, 2026, we repurchased $3.8 million of common stock at an average price of $8.30 per share, excluding related costs and fees. During the nine months ended September 30, 2026, we repurchased $5.6 million of common stock at an average price of $8.30 per share, excluding related costs and fees. As of September 30, 2026, we had exhausted the amount authorized for repurchasing shares of our common stock. All shares of common stock that we repurchased are held as treasury stock. Refer to Note 13, Subsequent Events, for information regarding additional amounts authorized under the 2025 SRP.
24
Treasury Stock
During the three and nine months ended September 30, 2026, shares of common stock at a total cost of $2 thousand and $77 thousand, respectively, were netted and surrendered as payment for minimum statutory withholding obligations in connection with the vesting of outstanding stock awards. During the three and nine months ended September 30, 2025, shares of common stock at a total cost of zero and $8 thousand, respectively, were netted and surrendered as payment for minimum statutory withholding obligations in connection with the vesting of outstanding stock awards. Shares surrendered by the participants in accordance with the applicable award agreements and plan are deemed repurchased by us, but are not part of publicly announced stock repurchase programs.
Note 8: Stock-Based Compensation
We grant stock-based awards under our 2024 Incentive Stock Plan (the “2024 Plan”). The shares issued as a result of stock-based compensation transactions generally have been funded with the issuance of new shares of our common stock. We may grant the following types of incentive awards under the 2024 Plan: (i) non-qualified stock options; (ii) incentive stock options; (iii) stock appreciation rights; (iv) restricted stock; and (v) restricted stock units. Each award granted under the 2024 Plan is subject to an award agreement that incorporates, as applicable, the exercise price, the term of the award, the periods of restriction, the number of shares to which the award pertains and such other terms and conditions as the plan committee determines. Awards granted under the 2024 Plan are classified as equity awards, which are recorded in stockholders’ equity in our condensed consolidated balance sheets. As of September 30, 2026, we have granted under the 2024 Plan: (i) non-qualified stock options; (ii) incentive stock options; and (iii) restricted stock. There were no stock appreciation rights and restricted stock units granted under the 2024 Plan as of September 30, 2026. As of September 30, 2026, 1,465,327 shares of common stock remained available for issuance under the 2024 Plan.
Stock Options
Our closing price on the date of grant is the basis of fair value of our common stock used in determining the value of share-based awards. To the extent the value of our share-based awards involves a measure of volatility, we use available historical volatility of our common stock over a period of time corresponding to the expected stock option term. We use the simplified method to calculate the expected term of stock option grants to employees. Accordingly, the expected life of the options granted is based on the average of the vesting term, which is generally four years and the contractual term, which is generally 10 years. The risk-free interest rate is based on United States Treasury yields in effect at the date of grant for periods corresponding to the expected stock option term. Forfeitures are estimated based on historical and forecasted turnover, which is approximately 5 %.
We did not
The information below summarizes the stock option activity for the nine months ended September 30, 2026:
| Stock Options | Number of Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Life (Years) | |||||||||||||||||
| Outstanding at December 31, 2025 | $ | |||||||||||||||||||
| Exercised | ( | |||||||||||||||||||
| Expired | ( | |||||||||||||||||||
| Outstanding at September 30, 2026 | $ | |||||||||||||||||||
| Exercisable at September 30, 2026 | $ | |||||||||||||||||||
For the three months ended September 30, 2026 and 2025, stock-based compensation expense for stock options was $15 thousand and $16 thousand, respectively. For the nine months ended September 30, 2026 and 2025, stock-based compensation expense for stock options was $43 thousand and $55 thousand, respectively.
Restricted Stock
Restricted stock awards granted to employees generally vest in four equal annual installments. Restricted stock awards granted to non-employee directors typically vest in full one year after the date of grant.
25
The information below summarizes the restricted stock activity for the nine months ended September 30, 2026:
| Restricted Stock Awards | Number of Shares | Weighted Average Grant-Date Fair Value per Award | ||||||||||||
| Non-vested at December 31, 2025 | $ | |||||||||||||
| Granted | ||||||||||||||
| Vested | ( | |||||||||||||
| Forfeited | ( | |||||||||||||
| Non-vested at September 30, 2026 | $ | |||||||||||||
For the three months ended September 30, 2026 and 2025, stock-based compensation expense for restricted stock awards was $321 thousand and $330 thousand, respectively. For the nine months ended September 30, 2026 and 2025, stock-based compensation expense for restricted stock awards was $996 thousand and $916 thousand, respectively.
Note 9: Income Taxes
Note 10: Commitments and Contingencies
Leases
The table below summarizes the components of lease expense and statements of operations location for the three and nine months ended September 30, 2026 and 2025:
| Line Items in our Condensed Consolidated Statements of Operations | Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||||||
| Operating lease costs: | |||||||||||||||||||||||||||||
| Operating lease costs | General and administrative expenses | $ | $ | $ | $ | ||||||||||||||||||||||||
| Total lease costs | $ | $ | $ | $ | |||||||||||||||||||||||||
26
Supplemental information and balance sheet location related to leases (excluding amounts related to leases classified as discontinued operations) were as follows:
| September 30, 2026 | December 31, 2025 | ||||||||||
| Operating Leases: | |||||||||||
| Operating lease right-of-use asset | $ | $ | |||||||||
| Operating lease liability - current portion | |||||||||||
| Operating lease liability - net of current portion | |||||||||||
| Total operating lease liability | $ | $ | |||||||||
| Weighted average remaining lease term (in years): | |||||||||||
| Operating leases | |||||||||||
| Weighted average discount rate: | |||||||||||
| Operating leases | % | % | |||||||||
Supplemental cash flow information related to leases (excluding amounts related to leases classified as discontinued operations) was as follows:
| Nine Months Ended September 30, | |||||||||||
| 2026 | 2025 | ||||||||||
| Cash paid for amounts included in measurement of liabilities: | |||||||||||
| Operating cash flows from operating leases | $ | $ | |||||||||
| Non-cash transactions: | |||||||||||
| ROU assets obtained in exchange for operating lease liabilities | $ | $ | |||||||||
Maturities of lease liabilities as of September 30, 2026 are as follows, excluding amounts related to leases classified as discontinued operations:
| Operating Leases | ||||||||
| 2026 (remainder) | $ | |||||||
| 2027 | ||||||||
| 2028 | ||||||||
| 2029 | ||||||||
| 2030 | ||||||||
| Thereafter | ||||||||
| Total lease payments | $ | |||||||
| Less: Imputed interest | ( | |||||||
| Total lease obligations | $ | |||||||
| Less: Current obligations | ( | |||||||
| Long-term lease obligation | $ | |||||||
Guaranties in Connection with the Sale of the Divested Business
In connection with the sale of company-owned or managed clinics, we have guaranteed 81 operating leases assumed by the buyers. We are obligated to perform under the guaranties if the buyers fail to perform under the lease agreements at any time during the remainder of the term of the lease agreements, the latest of which expires on February 28, 2035. As of September 30, 2026, the undiscounted maximum remaining lease payments totaled $11.7 million. We have recorded a $40 thousand liability with respect to our obligations under the guaranties for one lease as of September 30, 2026 and have not recorded a liability for the remaining guaranties as we concluded that payment under those guaranties was not probable.
27
Litigation
In the normal course of business, we are party to litigation and claims from time to time. We maintain insurance to cover certain litigation and claims.
During the second quarter of 2024, we entered into settlement agreements from litigation related to employment matters of $1.5 million that were outside the normal course of business, which we have accrued for in discontinued operations current liabilities as of December 31, 2025. The settlement was paid in full during the third quarter of 2026.
During the first quarter of 2025, litigation related to a medical injury claim between a patient (“the Claimant”) and us filed on September 5, 2023 reached a settlement agreement on February 25, 2025. Per the terms of the settlement agreement, we were required to pay the Claimant $3.4 million with our insurance. We accrued the settlement recorded in discontinued operations current liabilities for $3.4 million as of December 31, 2024. The expense of the accrual was offset by a receivable recorded as discontinued operations current assets from our insurance for $1.9 million as of December 31, 2024. The settlement was paid in full during the first quarter of 2025.
In 2025, we determined that the likelihood of a loss related to multiple lawsuits outside of the normal course of business, including three cases consolidated into one class action lawsuit (but not yet certified), six individual cases related to each other and two unrelated individual cases, all filed against us and a chiropractor employed by the professional corporation providing clinical services in 2024, 2025 and 2026 in the state of California, became probable. The initial lawsuit was filed against us on June 6, 2024 with the Superior Court of California in Los Angeles County. The lawsuits allege, among other claims, an invasion of privacy, negligence, emotional distress, sexual harassment, unlawful recording, failure to provide a safe environment and trespass on person at one of our former company-owned or managed clinics. The lawsuits are currently in discovery and trial is scheduled to begin in early 2027. We intend to continue to defend these cases vigorously, but it is not possible at this time to reasonably estimate the outcome of or any potential liability from these cases and therefore, no accrual exists as of September 30, 2026, with the exception of five individual cases related to the matter where we have booked an accrual that represents our insurance coverage deductible. We also note that our exposure to these cases may be limited by our insurance coverage, but the potential exposure is undetermined as of September 30, 2026.
Note 11: Segment Reporting
An operating segment is defined as a component of an enterprise for which discrete financial information is available and is reviewed regularly by the Chief Operating Decision Maker (the “CODM”) to evaluate performance and make operating decisions. We have identified the CODM as our Chief Executive Officer.
Historically, we have had two operating business segments: (1) Corporate Clinics, and (2) Franchise Operations. The Corporate Clinics segment is comprised of the activities of the company-owned or managed clinics. In the fourth quarter of 2024, as part of our refranchising strategy, the Corporate Clinic segment met the criteria to be reported as discontinued operations (Refer to Note 3, Divestitures for financial information on the discontinued operating Corporate Clinics segment). Therefore, since December 31, 2024, we have had only one reportable segment: Franchise Operations. In accordance with ASC 205-20, Discontinued Operations, expenses that in prior periods were partially allocated to the Corporate Clinic segment that are not wholly related to the activity of the segment have been recast to be presented in continuing operations, which is now Franchise Operations. Additionally, any expenses previously identified as Corporate Unallocated have been allocated entirely to the Franchise Operations segment.
The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue primarily from customers by providing access to our franchise license, which represents symbolic intellectual property (See Note 2, Revenue Disclosures for additional details). The Franchise Operations segment is managed on a consolidated basis because all operations are located within a similar economic and regulatory environment, provide the same services and share the same business model and pricing strategies. As of September 30, 2026, the franchise system consisted of 915 clinics in operation. The accounting policies for the franchise segment are the same as those described in Note 1, Nature of Operations and Summary of Significant Accounting Policies. The CODM uses Net Income, Gross Profit, Operating Income, and Adjusted EBITDA as metrics in assessing performance and determining how to allocate resources. Net Income, Gross Profit, and Operating Income are reported on the condensed consolidated statements of operations. Adjusted EBITDA is presented in Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations, Non-GAAP Financial Measures and is reconciled back to Net income (loss) from continuing operations on the condensed consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets, excluding discontinued operations current assets. The CODM uses these financial measures to evaluate income generated from segment
28
assets (return on assets) in deciding whether to reinvest profits in the Franchise Segment or into other parts of the entity, such as new products or services, new geographic territories, acquisitions or reacquisitions, or stock repurchases. Net Income and Adjusted EBITDA are used to monitor budget versus actual results. The CODM also uses Net Income and Adjusted EBITDA in conjunction with certain non-financial metrics in competitive analysis by benchmarking to our competitors. The competitive analysis along with the monitoring of budgeted versus actual results are used in assessing performance of the segment and in establishing management’s compensation.
The following table summarizes total revenue and significant expense categories and amounts for our reportable segment that aligns with the segment level information that is regularly provided to the CODM:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||
| Revenue | $ | $ | $ | $ | ||||||||||||||||||||||
| Less: | ||||||||||||||||||||||||||
| Franchise and regional developer cost of revenues | ||||||||||||||||||||||||||
| IT cost of revenues | ||||||||||||||||||||||||||
| Selling and marketing expenses | ||||||||||||||||||||||||||
| Adjusted general and administrative expenses | ||||||||||||||||||||||||||
| Stock-based compensation expense | ||||||||||||||||||||||||||
Other segment items, net (a) | ||||||||||||||||||||||||||
| Depreciation and amortization expense | ||||||||||||||||||||||||||
| Income tax expense | ||||||||||||||||||||||||||
| Segment income (loss) | $ | $ | $ | $ | ( | |||||||||||||||||||||
| Reconciliation of (loss) income | ||||||||||||||||||||||||||
| Net income (loss) from continuing operations | $ | $ | $ | $ | ( | |||||||||||||||||||||
| Net (loss) income from discontinued operations | ( | ( | ||||||||||||||||||||||||
| Net (loss) income | $ | ( | $ | $ | $ | |||||||||||||||||||||
_________________
(a) Other segment items, net includes other (income) loss, net, acquisition-related expenses, net loss on disposition or impairment, costs related to restatement filings, restructuring costs and litigation expenses.
Note 12: Related Party Transactions
Mr. Jefferson Gramm, Managing Partner of Bandera Partners LLC, who is a beneficial holder of more than 5% of our outstanding common stock (approximately 29 % as of September 30, 2026), was appointed to the Board of Directors effective as of January 2, 2024.
Marshall Gramm, who is a family member of Mr. Jefferson Gramm, owns four franchise licenses. One license was sold to Mr. Marshall Gramm in December 2020 for $40 thousand and three licenses were transferred from other franchisees in June 2022 to Mr. Marshall Gramm for a transfer fee of $15 18 thousand total (which reflects the $15 10 years from the date of transfer per our Franchise Disclosure Document).
These transactions involved terms no less favorable to us than those that would have been obtained in the absence of such affiliation. Although we have no way of estimating the aggregate amount of franchise fees, royalties, advertising fund fees, IT-related income and computer software fees that these franchisees will pay over the life of the franchise licenses, the franchisees affiliated with Mr. Jefferson Gramm are subject to such fees under the same terms and conditions as all other franchisees.
In October 2020, Mr. Jefferson Gramm loaned approximately $370 thousand to an unaffiliated franchisee that owns and operates one franchise clinic. The loan is not secured by the assets of the business and there are no foreclosure rights. As of September 30, 2026, the remaining balance on the unsecured loan was approximately $178 thousand.
29
Note 13: Subsequent Events
Regional Developer Rights
On October 1, 2026, we entered into an Asset Purchase Agreement (the “Texas Purchase Agreement”) with The Joint Franchises San Antonio, LLC, a Texas limited liability company, The Joint Franchises DFW, LLC, a Texas limited liability company, The Joint Franchises Houston, LLC, a Texas limited liability company, The Joint Franchises Austin, LLC, a Texas limited liability company, and The Joint Franchises Texas, Ltd., a Texas limited partnership, of which David Glover and Anne Glover, residents of Texas, are the limited partners (collectively, the “Texas Sellers”), pursuant to which we reacquired from the Texas Sellers certain regional development rights in the Texas region and mutually terminated the related regional developer agreements with the Texas Sellers in the Texas region (collectively, the “Texas RDAs”) for an aggregate purchase price of $8.0 million in cash that was due upon execution of the Texas Purchase Agreement. If certain gross sales metrics are met or exceeded under the Texas RDAs during the annual periods beginning September 1, 2026, we will also pay to the Texas Sellers up to $2.0 million in additional consideration payments, split evenly between the two years .
Stock Repurchase Program
On November 3, 2026, the Board of Directors authorized an additional $5.0 million under the 2025 SRP.
30
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2025 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 13, 2026.
Overview
We are a growing franchisor that uses a private pay, non-insurance, cash-based model. We will continue our franchised-focused expansion of chiropractic clinics in key markets throughout North America, and potentially abroad, as we seek to be the leading provider of chiropractic care in the markets we serve and to become the most recognized brand in our industry.
Key Performance Measures. We receive monthly performance reports from our system and our clinics that include key performance indicators per clinic, including gross sales, comparable same-store sales growth, or “Comp Sales,” number of new patients, conversion percentage and membership attrition. In addition, we review monthly reporting related to system-wide sales, clinic openings, clinic license sales, Adjusted EBITDA (Refer to Non-GAAP Financial Measures for more information on Adjusted EBITDA) and various earnings metrics in the aggregate and per clinic. We believe these indicators provide us with useful data with which to measure our performance and to measure our franchisees’ and clinics’ performance. Comp Sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open for at least 13 full months and exclude any clinics that have closed. System-wide sales include sales at all clinics, whether operated by us or by franchisees. While franchised clinic sales are not recorded as revenues by us, management believes the information is important in understanding the overall brand’s financial performance, because these sales are the basis on which we calculate and record royalty fees and are indicative of the financial health of the franchisee base.
For the three months ended September 30, 2026, compared to the prior year period:
•Comp sales of clinics that have been open for at least 13 full months decreased 1.9%; and
•System-wide sales for all clinics open for any amount of time decreased 3.1% to $123.3 million.
Key Clinic Development Trends. As of September 30, 2026, we and our franchisees operated or managed 930 clinics, of which 915 were operated or managed by franchisees and 15 were operated as company-owned or managed clinics. Our franchisees opened four clinics in the third quarter of 2026, compared to nine clinics in the third quarter of 2025.
Our current strategy is to grow through the sale and development of additional franchises. After evaluating options for improvement, during 2023, our Board of Directors authorized management to initiate a plan to refranchise or sell the majority of our company-owned or managed clinics. During the third quarter of 2024, we expanded the refranchising plan to include the full portfolio of our company-owned or managed clinics, marketing the clinics in large clusters grouped primarily by geographic location. This refined strategy will leverage our greatest strength – our capacity to build a franchise – to drive long-term growth for both our franchisees and The Joint as a public company. During the first quarter of 2025, we received draft letters of intent (“LOIs”) for our full portfolio of company-owned or managed clinics. During the second quarter of 2025, we refranchised 37 clinics and during the third quarter of 2025, we refranchised one clinic.
On June 30, 2025, we closed on the sale of 31 company-owned or managed clinics and associated franchise licenses in Arizona and New Mexico to an existing franchisee, Joint Ventures, LLC, in exchange for $8.3 million in cash and the regional developer territory rights of the Northwest region. We carried an upfront regional developer fee liability balance associated with this transaction of $42 thousand, representing the unrecognized fee collected upon the execution of the regional developer agreement. We accounted for the reacquisition of the regional developer rights as a release of liability and were included as part of the total consideration received to calculate the gain or loss on the sale. Losses on the sale were included with the loss on the sale of assets included in Net loss on disposition or impairment from discontinued operations. As part of the sale, Joint Ventures, LLC agreed to open another 10 clinics in the same region. Additionally, on June 23, 2025, we closed the sale of five clinics along with future development rights in the Kansas City region to an existing franchisee, Chiro 93 LLC.
On December 5, 2025, we entered into an Asset Purchase Agreement with Addisco Value, LLC, a North Carolina limited liability company, Triangle Chiropractic Associates P.C., a North Carolina professional corporation, and Bluffton TJ, LLC, a South Carolina limited liability company, collectively as buyers, pursuant to which we will sell the assets of, and grant franchise rights
31
to, 22 company-owned or managed clinics located in Virginia, North Carolina and South Carolina for an aggregate purchase price of approximately $1.5 million, subject to certain adjustments. In mid-December 2025, the buyers assumed business operations under MSAs that will remain in effect until lease reassignments are completed to permit ownership transfer. During the quarter ended June 30, 2026, we closed on the sale of one clinic included in the transaction. During the quarter ended September 30, 2026, we closed on the sale of nine clinics included in the transaction. As of September 30, 2026, the transaction as a whole had not officially closed and therefore, the net assets and liabilities of the remaining clinics remain in our consolidated balance sheets.
On April 20, 2026, we entered into the Elite Chiro Group Purchase Agreement with Elite Chiro Group, pursuant to which we will sell to Elite Chiro Group the assets of, and grant franchise rights to, 45 company-owned or managed clinics located in Southern California for an aggregate purchase price of $2.3 million, subject to certain adjustments. The Purchase Price includes prorated franchise fees pursuant to 45 separate franchise agreements to be entered into between us and Elite Chiro Group and the non-exclusive development rights for 10 clinics to be developed in the metropolitan statistical areas of a development area to be agreed upon by us and Elite Chiro Group in accordance with the schedule set forth in the Elite Chiro Group Purchase Agreement. The closing of each clinic as part of the Elite Chiro Group Transaction is expressly conditioned upon the assignment of the existing lease for such clinic. On April 27, 2026, we closed on the sale of 13 clinics included in the Elite Chiro Group Transaction, at which time ownership of such clinics transferred to Elite Chiro Group. On April 27, 2026, Elite Chiro Group also assumed business operations for the remaining 32 clinics included in the Elite Chiro Group Transaction pursuant to an MSA. During the quarter ended June 30, 2026, we closed on the sale of 15 additional clinics included in the Elite Chiro Group Transaction. During the quarter ended September 30, 2026, we closed on the sale of 12 additional clinics included in the Elite Chiro Group Transaction. As of September 30, 2026, the Elite Chiro Group Transaction as a whole had not officially closed and therefore, the net assets and liabilities of the remaining clinics remain in our consolidated balance sheets.
On June 28, 2026, we entered into an Asset Purchase Agreement (the “Vigeo Purchase Agreement”) with Vigeo, LLC, a California limited liability company (“Vigeo”), as buyer, pursuant to which we will sell the assets of, and grant franchise rights to, four company-owned or managed clinics located in Northern California for an aggregate purchase price of $400 thousand. Pursuant to the Vigeo Purchase Agreement, Vigeo paid $113 thousand of the purchase price as a down payment upon the close of the transaction under the Vigeo Purchase Agreement and will pay the remaining balance of the purchase price pursuant to separate promissory notes and corresponding security agreements. As of September 30, 2026, we have closed on the sale of the four company-owned or managed clinics included in the Vigeo Purchase Agreement and have recorded a $287 thousand note receivable that will be paid in full upon the maturity date of October 1, 2028.
On March 31, 2026, we acquired the regional developer territory rights from one of our regional developers. We carried an upfront regional developer fee liability balance associated with this transaction of $37 thousand, representing the unrecognized fee collected upon the execution of the regional developer agreement. During the quarter ended June 30, 2026, we acquired the regional developer territory rights from three of our regional developers. We carried an upfront regional developer fee liability balance associated with these transactions of $80 thousand, representing the unrecognized fee collected upon the execution of the regional developer agreement.
On October 1, 2026, we entered into the Texas Purchase Agreement with the Texas Sellers, pursuant to which we reacquired from the Texas Sellers certain regional development rights in the Texas region and mutually terminated the Texas RDAs. As of October 1, 2026, the Texas region included 141 franchised clinics, and following the transaction under the Texas Purchase Agreement, the Texas Sellers will continue to franchise eight clinics in Texas through their affiliates.
The Texas RDAs were among our earliest regional developer agreements and include several negotiated terms, such as renewal rights for multiple successive 10-year terms. Pursuant to the Texas RDAs, the Texas Sellers received approximately $2.3 million in royalties paid by franchisees in the Texas region during the trailing 12 months ended August 31, 2026. Based on the foregoing, we agreed to pay to the Texas Sellers an aggregate purchase price of $8.0 million in cash that was due upon execution of the Texas Purchase Agreement, and if certain gross sales metrics are met or exceeded under the Texas RDAs during the two annual periods beginning September 1, 2026, we will also pay to the Texas Sellers up to $2.0 million in additional consideration payments, split evenly between the two years.
Our goal will be to generate significant proceeds that will provide us with value creating capital allocation opportunities. These opportunities could include, but are not limited to, reinvestment in the brand and related marketing, continued investment in our IT platforms, the repurchase of regional development territories, certain merger or acquisition opportunities and/or additional stock repurchase programs.
The number of franchise licenses sold for the third quarter of 2026 was one, compared with 13 licenses sold for the third quarter of 2025. We ended the third quarter of 2026 with 11 regional developers who were responsible for one, or 9%, of the 11 licenses
32
sold during the year. We will continue to leverage the power of the regional developer program to accelerate the number of clinics sold, and eventually opened, across the country and will continue to evaluate opportunities to bring regional development territories under our direct structure as we advance our long-term growth strategy and expands access to chiropractic care in communities nationwide.
We believe that we continue to have a sound business concept and will benefit from the fundamental changes taking place in the manner in which Americans access chiropractic care and their growing interest in seeking effective, affordable natural solutions for general wellness. These trends join with the preference we have seen among chiropractic doctors to reject the insurance-based model resulting in a combination that benefits the consumer and the service provider alike. We believe that these forces create an important opportunity to accelerate the growth of our network.
Significant Events and/or Recent Developments
Recent events that may impact our business include unfavorable global economic or political conditions, continued labor shortages, elevated gas prices, and inflation and other cost increases. We anticipate that 2026 will continue to be a volatile macroeconomic environment.
The primary inflationary factor affecting our operations is labor costs. Beginning in 2024 and continuing into 2026, clinics owned or managed by us or our franchisees were negatively impacted by labor shortages and wage increases, which increased our general and administrative expenses. Further, should we fail to continue to increase our wages competitively in response to increasing wage rates, the quality of our workforce could decline, causing our patient service to suffer. While we anticipate that these continued headwinds can be partially mitigated by pricing actions, there can be no assurance that we will be able to continue to take such pricing actions. A continued increase in labor costs could have an adverse effect on our operating costs, financial condition and results of operations.
In addition, the expectation that interest rates will remain elevated may adversely affect patients’ financial conditions, resulting in reduced spending on our services. While the impact of these factors continues to remain uncertain, we will continue to evaluate the extent to which these factors will impact our business, financial condition, or results of operations. These and other uncertainties with respect to these recent events could result in changes to our current expectations.
Stock Repurchase Program
On June 3, 2025, our Board of Directors approved the 2025 SRP to repurchase up to $5.0 million of our common stock, par value $0.001 per share, from time to time until June 3, 2027 or such other date as we have exhausted, or the Board of Directors otherwise terminates, the repurchase authorization. The timing, volume, price, and terms of the repurchases will depend on market and business conditions, applicable legal requirements, and other factors. The repurchases may be made on the open market, in privately negotiated transactions, or in such other manner (e.g., accelerated share repurchase transactions, block trades, derivatives, or otherwise) that complies with the terms of applicable federal and state securities laws and regulations. On November 4, 2025, the Board of Directors authorized an additional $12.0 million under the 2025 SRP and extended the repurchase date through November 4, 2027.
During the nine months ended September 30, 2026, we repurchased 680,057 shares of our common stock for approximately $5.6 million. Shares repurchased during the nine months ended September 30, 2026 represented 4.8% of outstanding common stock at December 31, 2025. All shares of common stock that were repurchased are held as treasury stock. As of September 30, 2026, we had exhausted the amount authorized for repurchasing shares of our common stock under the 2025 SRP.
On November 3, 2026, the Board of Directors authorized an additional $5.0 million under the 2025 SRP.
Factors Affecting Our Performance
Our operating results may fluctuate significantly as a result of a variety of factors, including the timing of new clinic sales, openings, closures, markets in which they are contained and related expenses, general economic conditions, cost inflation, labor shortages, elevated gas prices, consumer confidence in the economy, consumer preferences, competitive factors, and disease epidemics and other health-related concerns.
33
Critical Accounting Policies and Estimates
There were no changes in our critical accounting policies and estimates during the three months ended September 30, 2026, from those set forth in “Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K for the year ended December 31, 2025.
Results of Operations
The following discussion and analysis of our financial results encompasses the results of our Franchise Operations business segment for the three and nine months ended September 30, 2026, compared with the three and nine months ended September 30, 2025. All financial results and metrics discussed below are on a continuing operations basis.
Total Revenues - Three Months Ended September 30, 2026 Compared with Three Months Ended September 30, 2025
Components of revenues were as follows:
| Three Months Ended September 30, | |||||||||||||||||||||||
| 2026 | 2025 | Change from Prior Year | Percent Change from Prior Year | ||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||
| Royalty fees | $ | 8,254,366 | $ | 8,106,915 | $ | 147,451 | 1.8 | % | |||||||||||||||
| Franchise fees | 893,882 | 964,796 | (70,914) | (7.4) | |||||||||||||||||||
| Advertising fund revenue | 2,391,339 | 2,344,833 | 46,506 | 2.0 | |||||||||||||||||||
| Software fees | 1,578,567 | 1,545,331 | 33,236 | 2.2 | |||||||||||||||||||
| Other revenues | 433,554 | 418,810 | 14,744 | 3.5 | |||||||||||||||||||
| Total revenues | $ | 13,551,708 | $ | 13,380,685 | $ | 171,023 | 1.3 | ||||||||||||||||
Total revenues increased by $0.2 million, primarily due to the continued expansion and revenue growth of our franchise base and included:
•Royalty fees, software fees and advertising fund revenue increased due to an increase in the number of franchised clinics in operation during the current period. As of September 30, 2026 and 2025, there were 915 and 884 franchised clinics in operation, respectively.
•Franchise fees decreased primarily due to a lower impact of accelerated revenue recognition resulting from terminated franchise license agreements and related fees, with five and 12 franchise license agreements terminated during the three months ended September 30, 2026 and 2025, respectively.
Total Revenues - Nine Months Ended September 30, 2026 Compared with Nine Months Ended September 30, 2025
Components of revenues were as follows:
| Nine Months Ended September 30, | |||||||||||||||||||||||
| 2026 | 2025 | Change from Prior Year | Percent Change from Prior Year | ||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||
| Royalty fees | $ | 24,614,204 | $ | 24,311,022 | $ | 303,182 | 1.2 | % | |||||||||||||||
| Franchise fees | 2,789,537 | 2,561,415 | 228,122 | 8.9 | |||||||||||||||||||
| Advertising fund revenue | 9,754,259 | 6,985,030 | 2,769,229 | 39.6 | |||||||||||||||||||
| Software fees | 4,660,799 | 4,488,959 | 171,840 | 3.8 | |||||||||||||||||||
| Other revenues | 1,735,056 | 1,382,119 | 352,937 | 25.5 | |||||||||||||||||||
| Total revenues | $ | 43,553,855 | $ | 39,728,545 | $ | 3,825,310 | 9.6 | ||||||||||||||||
34
Total revenues increased by $3.8 million, primarily due to the continued expansion and revenue growth of our franchise base and included:
•Royalty fees and software fees increased due to an increase in the number of franchised clinics in operation during the current period.
•Franchise fees increased primarily due to the impact of accelerated revenue recognition resulting from terminated franchise license agreements and related fees, with 38 and 30 franchise license agreements terminated during the nine months ended September 30, 2026 and 2025, respectively.
•Advertising fund revenue increased due to additional funds contributed to the National Marketing Fund by our franchisees, in addition to the historical 2% of gross sales, that initiated in the fourth quarter of 2025 and continued through the second quarter of 2026.
•Other revenues increased primarily due to an increase in sponsorship revenue related to our annual conference held in April 2026.
Cost of Revenues
| Cost of Revenues | 2026 | 2025 | Change from Prior Year | Percent Change from Prior Year | ||||||||||||||||||||||
| Three Months Ended September 30, | $ | 2,403,568 | $ | 2,661,234 | $ | (257,666) | (9.7) | % | ||||||||||||||||||
| Nine Months Ended September 30, | 7,603,473 | 8,405,967 | (802,494) | (9.5) | ||||||||||||||||||||||
For the three and nine months ended September 30, 2026, as compared with the three and nine months ended September 30, 2025, the total cost of revenues decreased primarily due to a reduction in regional developer royalties driven by the five regional developer territory rights acquired on or after June 30, 2025.
Selling and Marketing Expenses
| Selling and Marketing Expenses | 2026 | 2025 | Change from Prior Year | Percent Change from Prior Year | ||||||||||||||||||||||
| Three Months Ended September 30, | $ | 2,704,777 | $ | 2,816,081 | $ | (111,304) | (4.0) | % | ||||||||||||||||||
| Nine Months Ended September 30, | 11,307,832 | 9,805,075 | 1,502,757 | 15.3 | ||||||||||||||||||||||
For the three months ended September 30, 2026, as compared with the three months ended September 30, 2025, selling and marketing expenses decreased slightly due to lower system-wide sales.
For the nine months ended September 30, 2026, as compared with the nine months ended September 30, 2025, selling and marketing expenses increased due to an increase in expenses associated with our national marketing campaign efforts, which began late in the fourth quarter of 2025.
Depreciation and Amortization Expenses
| Depreciation and Amortization Expenses | 2026 | 2025 | Change from Prior Year | Percent Change from Prior Year | ||||||||||||||||||||||
| Three Months Ended September 30, | $ | 261,779 | $ | 446,736 | $ | (184,957) | (41.4) | % | ||||||||||||||||||
| Nine Months Ended September 30, | 1,081,333 | 1,210,961 | (129,628) | (10.7) | ||||||||||||||||||||||
Depreciation and amortization expenses decreased for the three and nine months ended September 30, 2026, as compared to the three and nine months ended September 30, 2025, primarily due to lower depreciation expenses driven by the now fully depreciated IT platform used by our clinics for the management of operations, which was put into service in July 2021.
35
General and Administrative Expenses
| General and Administrative Expenses | 2026 | 2025 | Change from Prior Year | Percent Change from Prior Year | ||||||||||||||||||||||
| Three Months Ended September 30, | $ | 6,851,612 | $ | 7,295,719 | $ | (444,107) | (6.1) | % | ||||||||||||||||||
| Nine Months Ended September 30, | 21,492,814 | 21,955,915 | (463,101) | (2.1) | ||||||||||||||||||||||
For the three months ended September 30, 2026, as compared with the three months ended September 30, 2025, general and administrative expenses decreased primarily due to a decrease in payroll and other employee compensation expenses including workers' compensation insurance driven by additional progress in our refranchising strategy and decreases in severance expense. As a percentage of revenue, general and administrative expenses during the three months ended September 30, 2026 and 2025 were 51% and 55%, respectively.
For the nine months ended September 30, 2026, as compared with the nine months ended September 30, 2025, general and administrative expenses decreased primarily due to a decrease in payroll and other employee compensation expenses including workers' compensation insurance driven by additional progress in our refranchising strategy, partially offset by an increase in professional services, litigation and acquisition-related expenses. As a percentage of revenue, general and administrative expenses during the nine months ended September 30, 2026 and 2025 were 49% and 55%, respectively.
Included in general and administrative expenses from continuing operations above are expenses of $0.9 million related to workers’ compensation insurance for the nine months ended September 30, 2025, of which we believe that approximately $0.8 million relate to expenses that will not be incurred upon the completion of our refranchising strategy.
Other Income, Net
| Other Income, Net | 2026 | 2025 | Change from Prior Year | Percent Change from Prior Year | ||||||||||||||||||||||
| Three Months Ended September 30, | $ | 136,417 | $ | 139,801 | $ | (3,384) | (2.4) | % | ||||||||||||||||||
| Nine Months Ended September 30, | 503,090 | 485,640 | 17,450 | 3.6 | ||||||||||||||||||||||
For the three months ended September 30, 2026, as compared with the three months ended September 30, 2025, other income decreased primarily due to lower average cash and cash equivalent balances in our money market funds resulting in decreased interest income.
For the nine months ended September 30, 2026, as compared with the nine months ended September 30, 2025, other income increased primarily due to the reversal of a liability related to the employee retention credit funds we received from the Internal Revenue Service in 2023.
Income Tax Expense
| Income Tax Expense | 2026 | 2025 | Change from Prior Year | Percent Change from Prior Year | ||||||||||||||||||||||
| Three Months Ended September 30, | $ | 10,069 | $ | 10,346 | $ | (277) | (2.7) | % | ||||||||||||||||||
| Nine Months Ended September 30, | 30,289 | 35,140 | (4,851) | (13.8) | ||||||||||||||||||||||
Income tax expense decreased during the three and nine months ended September 30, 2026, compared to the three and nine months ended September 30, 2025, primarily due to a decrease in estimated state income taxes.
36
Recent Accounting Pronouncements
See Note 1, Nature of Operations and Summary of Significant Accounting Policies, to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for information regarding recently issued accounting pronouncements that may impact our financial statements.
Non-GAAP Financial Measures
The tables below reconcile net (loss) income to Adjusted EBITDA for the three and nine months ended September 30, 2026 and 2025:
| Three Months Ended September 30, | |||||||||||||||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||||||||||||||
| From Continuing Operations | From Discontinued Operations | Net Operations | From Continuing Operations | From Discontinued Operations | Net Operations | ||||||||||||||||||||||||||||||
| Non-GAAP Financial Data: | |||||||||||||||||||||||||||||||||||
| Net income (loss) | $ | 1,456,320 | $ | (1,573,680) | $ | (117,360) | $ | 290,370 | $ | 564,639 | $ | 855,009 | |||||||||||||||||||||||
| Net interest income | (136,417) | — | (136,417) | (253,277) | — | (253,277) | |||||||||||||||||||||||||||||
| Depreciation and amortization expense | 261,779 | 134 | 261,913 | 446,736 | 16,310 | 463,046 | |||||||||||||||||||||||||||||
| Income tax expense (benefit) | 10,069 | (20,197) | (10,128) | 10,346 | 99,630 | 109,976 | |||||||||||||||||||||||||||||
| EBITDA | 1,591,751 | (1,593,743) | (1,992) | 494,175 | 680,579 | 1,174,754 | |||||||||||||||||||||||||||||
| Stock-based compensation expense | 335,572 | — | 335,572 | 346,209 | — | 346,209 | |||||||||||||||||||||||||||||
| Net loss on disposition or impairment | — | 2,084,596 | 2,084,596 | — | 860,598 | 860,598 | |||||||||||||||||||||||||||||
| Costs related to restatement filings | — | — | — | 113,477 | — | 113,477 | |||||||||||||||||||||||||||||
| Restructuring costs | 192,156 | 109,492 | 301,648 | 355,042 | 102,024 | 457,066 | |||||||||||||||||||||||||||||
| Litigation expenses | 148,480 | 401,943 | 550,423 | 100,000 | 250,000 | 350,000 | |||||||||||||||||||||||||||||
| Adjusted EBITDA | $ | 2,267,959 | $ | 1,002,288 | $ | 3,270,247 | $ | 1,408,903 | $ | 1,893,201 | $ | 3,302,104 | |||||||||||||||||||||||
37
| Nine Months Ended September 30, | |||||||||||||||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||||||||||||||
| From Continuing Operations | From Discontinued Operations | Net Operations | From Continuing Operations | From Discontinued Operations | Net Operations | ||||||||||||||||||||||||||||||
| Non-GAAP Financial Data: | |||||||||||||||||||||||||||||||||||
| Net income (loss) | $ | 2,307,784 | $ | (472,988) | $ | 1,834,796 | $ | (1,205,286) | $ | 3,121,454 | $ | 1,916,168 | |||||||||||||||||||||||
| Net interest (income) expense | (504,605) | — | (504,605) | (599,116) | 239 | (598,877) | |||||||||||||||||||||||||||||
| Depreciation and amortization expense | 1,081,333 | 9,581 | 1,090,914 | 1,210,961 | 59,815 | 1,270,776 | |||||||||||||||||||||||||||||
| Income tax expense | 30,289 | 159,613 | 189,902 | 35,140 | 303,243 | 338,383 | |||||||||||||||||||||||||||||
| EBITDA | 2,914,801 | (303,794) | 2,611,007 | (558,301) | 3,484,751 | 2,926,450 | |||||||||||||||||||||||||||||
| Stock-based compensation expense | 1,038,752 | — | 1,038,752 | 971,138 | — | 971,138 | |||||||||||||||||||||||||||||
| Acquisition-related expenses | 332,005 | — | 332,005 | — | — | — | |||||||||||||||||||||||||||||
| Net loss on disposition or impairment | 233,420 | 3,278,826 | 3,512,246 | 6,413 | 3,746,449 | 3,752,862 | |||||||||||||||||||||||||||||
| Costs related to restatement filings | — | — | — | 113,477 | — | 113,477 | |||||||||||||||||||||||||||||
| Restructuring costs | 932,493 | 166,275 | 1,098,768 | 910,619 | 371,739 | 1,282,358 | |||||||||||||||||||||||||||||
| Litigation expenses | 495,174 | 823,719 | 1,318,893 | 100,000 | 250,000 | 350,000 | |||||||||||||||||||||||||||||
| Adjusted EBITDA | $ | 5,946,645 | $ | 3,965,026 | $ | 9,911,671 | $ | 1,543,346 | $ | 7,852,939 | $ | 9,396,285 | |||||||||||||||||||||||
Adjusted EBITDA from continuing operations consists of net income (loss) from continuing operations before interest, income taxes, depreciation and amortization, acquisition-related expenses (which includes contract termination costs associated with reacquired regional developer rights), stock-based compensation expense, bargain purchase gain, (gain) loss on disposition or impairment, costs related to restatement filings, restructuring costs (consisting of non-recurring refranchising costs of all company-owned or managed clinics and non-recurring expenses related to changes to our senior leadership team), and litigation expenses (consisting of legal and related fees for specific proceedings that arise outside of the normal course of our business). We have provided Adjusted EBITDA, a non-GAAP measure of financial performance, because it is commonly used for comparing companies in our industry. You should not consider Adjusted EBITDA as a substitute for operating profit as an indicator of our operating performance or as an alternative to cash flows from operating activities as a measure of liquidity. We may calculate Adjusted EBITDA differently from other companies.
We believe that the use of Adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial measures with other outpatient medical clinics, which may present similar non-GAAP financial measures to investors. In addition, you should be aware when evaluating Adjusted EBITDA in the future we may incur unadjusted expenses similar to those currently excluded when calculating these measures. Our presentation of these measures should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Our computation of Adjusted EBITDA may not be comparable to other similarly titled measures computed by other companies, because all companies do not calculate Adjusted EBITDA in the same manner.
Our management does not consider Adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recorded in our financial statements. These limitations include, but are not limited to, the following:
•Adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;
•Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
•While not included in the presented periods, Adjusted EBITDA does not reflect the interest expense, or the cash requirements necessary to service interest or principal payments, on our debts;
•Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements;
38
•Adjusted EBITDA does not reflect the (gain) loss on disposition or impairment, which represents the impairment of assets as of the reporting date. We do not consider this to be indicative of our ongoing operations; and
•While not included in the presented periods, Adjusted EBITDA would not reflect any bargain purchase gain, which would represent the excess of the fair value of net assets acquired over the purchase consideration.
Because of these limitations, Adjusted EBITDA should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. We compensate for these limitations by relying primarily on our GAAP results and using Adjusted EBITDA only supplementally. You should review the reconciliation of Net income (loss) to Adjusted EBITDA above and not rely on any single financial measure to evaluate our business.
Liquidity and Capital Resources
Sources of Liquidity
As of September 30, 2026, we had unrestricted cash and short-term bank deposits of $18.3 million. We generated $0.6 million of cash flow from operating activities from both continuing and discontinued operations in the nine months ended September 30, 2026. Subsequent to quarter end, on October 1, 2026, we paid $8.0 million in cash under the Texas Purchase Agreement described in Note 13, Subsequent Events, and we may pay up to an additional $2.0 million contingent on annual gross sales metrics in the two annual periods beginning September 1, 2026, split evenly between the two years. While unfavorable global economic or political conditions create potential liquidity risks, as discussed further below, we believe that our existing cash and cash equivalents, our anticipated cash flows from operations and amounts available under our line of credit will be sufficient to fund our anticipated operating and investment needs for at least the next 12 months.
While the interruptions, delays and/or cost increases resulting from political instability and geopolitical tensions, adverse weather conditions, economic weakness, inflationary pressures, elevated interest rates, labor shortages, elevated gas prices and other factors have created uncertainty as to general economic conditions for the remainder of 2026, as of the date of this Quarterly Report on Form 10-Q, we believe that we have adequate capital resources and sufficient access to external financing sources to satisfy our current and reasonably anticipated requirements for funds to conduct our operations and meet other needs in the ordinary course of our business. For the remainder of 2026, we expect to use or redeploy our cash resources to support our business within the context of prevailing market conditions, which, given the ongoing uncertainties described above, could rapidly and materially deteriorate or otherwise change. Our long-term capital requirements, primarily for corporate initiatives, could be dependent on our ability to access additional funds through the debt and/or equity markets. If the equity and credit markets deteriorate, including as a result of economic weakness, political unrest or war, or any other reason, it may make any necessary equity or debt financing more difficult to obtain in a timely manner and on favorable terms, if at all, and if obtained, it may be more costly or more dilutive. From time to time, we consider and evaluate transactions related to our portfolio and capital structure, including debt financings, equity issuances, purchases and sales of assets, and other transactions. Given the ongoing uncertainties described above, the levels of our cash flows from operations for the remainder of 2026 may be impacted. There can be no assurance that we will be able to generate sufficient cash flows or obtain the capital necessary to meet our short and long-term capital requirements.
Analysis of Cash Flows
Net cash provided by operating activities for both continuing and discontinued operations increased by $1.6 million to $0.6 million for the nine months ended September 30, 2026, compared to net cash used in operating activities of $1.1 million for the nine months ended September 30, 2025. The increase in net cash provided by operating activities was primarily attributable to a change in accrued expenses of $2.2 million primarily related to a settlement payment of a medical injury claim during the first quarter of 2025 which was partially offset by a settlement payment of a employment matter during the third quarter of 2026 and a $1.7 million change in operating leases driven by the continued disposition of our corporate-owned or managed clinics and their related lease obligations as well as rent concessions during the first quarter of 2026 for our corporate headquarters. The increases in net cash provided by operating activities above were partially offset by a change in accounts receivable of $1.2 million due primarily to insurance recoveries received during the first quarter of 2025 and a change in payroll liabilities of $1.0 million related to the increased payout of our annual bonuses.
Net cash provided by investing activities was $0.6 million for the nine months ended September 30, 2026, compared to net cash provided by investing activities of $6.6 million for the nine months ended September 30, 2025. For the nine months ended September 30, 2026, this included proceeds from sales of clinics of $1.4 million, partially offset by purchases of property and equipment of $0.9 million. For the nine months ended September 30, 2025, this included proceeds from sales of clinics of $7.8 million, partially offset by purchases of property and equipment of $1.2 million.
39
Net cash used in financing activities for the nine months ended September 30, 2026 was $5.7 million, compared to net cash used in financing activities of $0.8 million for the nine months ended September 30, 2025. For the nine months ended September 30, 2026, net cash used in financing activities primarily included $5.6 million of common stock purchases under the 2025 SRP. For the nine months ended September 30, 2025, net cash used in financing activities included $2.3 million of common stock purchases under the 2025 SRP, partially offset by cash receipts from stock option exercises of $1.5 million.
Capital Composition
As discussed in the “Significant Events and/or Recent Developments” section of this MD&A, our Board of Directors approved the 2025 SRP to repurchase up to $17.0 million of our common stock. During the nine months ended September 30, 2026, we repurchased 680,057 shares under the 2025 SRP. Refer to the “Significant Events and/or Recent Developments” section above for more information and Part II, Item 2, “Unregistered Sales of Equity Securities and Use of Proceeds” of this Quarterly Report on Form 10-Q for our monthly repurchase activity during the three months ended September 30, 2026.
Off-Balance Sheet Arrangements
During the nine months ended September 30, 2026, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As of September 30, 2026, there have been no material changes to the quantitative and qualitative disclosures about market risk appearing in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” of our Annual Report on Form 10-K for the year ended December 31, 2025.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2026. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our disclosure controls and procedures were designed to provide reasonable assurance of achieving such objectives, and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2026, our management concluded that as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Information regarding our legal proceedings is discussed in Note 10, Commitments and Contingencies to our condensed consolidated financial statements, which is incorporated herein by reference.
ITEM 1A. RISK FACTORS
40
We documented our risk factors in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes to our risk factors since the filing of our Annual Report on Form 10-K for the year ended December 31, 2025.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
On June 3, 2025, our Board of Directors approved the 2025 SRP to repurchase up to $5.0 million of our common stock, par value $0.001 per share, from time to time until June 3, 2027 or such other date as we have exhausted, or the Board of Directors otherwise terminates, the repurchase authorization. On November 4, 2025, the Board of Directors authorized an additional $12.0 million under the 2025 SRP and extended the repurchase date through November 4, 2027. The timing, volume, price, and terms of the repurchases will depend on market and business conditions, applicable legal requirements, and other factors. The repurchases may be made on the open market, in privately negotiated transactions, or in such other manner (e.g., accelerated share repurchase transactions, block trades, derivatives, or otherwise) that complies with the terms of applicable federal and state securities laws and regulations.
The following table summarizes our monthly common stock repurchase activity during the three months ended September 30, 2026:
| Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Repurchased as Part of the 2025 SRP | Approximate Dollar Value of Shares that May Yet be Purchased Under the 2025 SRP | ||||||||||||||||||||||
| Repurchases from July 1 - 31, 2026 | — | $ | — | — | $ | 3,834,262 | ||||||||||||||||||||
| Repurchases from August 1 - 31, 2026 | 162,695 | 8.38 | 162,695 | 2,471,399 | ||||||||||||||||||||||
| Repurchases from September 1 - 30, 2026 | 298,069 | 8.26 | 298,069 | — | ||||||||||||||||||||||
| Total | 460,764 | $ | 8.30 | 460,764 | — | |||||||||||||||||||||
On November 3, 2026, the Board of Directors authorized an additional $5.0 million under the 2025 SRP.
ITEM 5. OTHER INFORMATION
During the quarter ended September 30, 2026, no director or officer of our company adopted terminated
41
ITEM 6. EXHIBITS
EXHIBIT INDEX
| Exhibit Number | Description of Document | |||||||
| 31.1* | ||||||||
| 31.2* | ||||||||
| 32.1** | ||||||||
| 101.INS | XBRL Instance Document. | |||||||
| 101.SCH | XBRL Taxonomy Extension Schema Document. | |||||||
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. | |||||||
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. | |||||||
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. | |||||||
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | |||||||
| * | Filed herewith | |||||||
| ** | Furnished herewith, not filed | |||||||
42
THE JOINT CORP.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized.
| THE JOINT CORP. | ||||||||
| Dated: November 5, 2026 | By: | /s/ Sanjiv Razdan | ||||||
| Sanjiv Razdan Chief Executive Officer and President (Principal Executive Officer) | ||||||||
| Dated: November 5, 2026 | By: | /s/ Scott J. Bowman | ||||||
| Scott J. Bowman Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | ||||||||
43
Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO RULES 13a-14(a) AND 15a-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934
I, Sanjiv Razdan, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 of The Joint Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: November 5, 2026
| /s/ Sanjiv Razdan | |||||
| Sanjiv Razdan President and Chief Executive Officer (Principal Executive Officer) | |||||
Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO RULES 13a-14(a) AND 15a-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934
I, Scott Bowman, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 of The Joint Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: November 5, 2026
| /s/ Scott J. Bowman | |||||
| Scott J. Bowman Chief Financial Officer (Principle Financial Officer and Principle Accounting Officer) | |||||
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of The Joint Corp. (the “Company”), for the quarter ended September 30, 2026, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned hereby certifies, in his or her capacity as an officer of the Company, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| By: | /s/ Sanjiv Razdan | |||||||
| Sanjiv Razdan President and Chief Executive Officer (Principal Executive Officer) | ||||||||
| Dated: November 5, 2026 | ||||||||
| By: | /s/ Scott J. Bowman | |||||||
| Scott J. Bowman Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | ||||||||
| Dated: November 5, 2026 | ||||||||